Review

Function of Nr4a Orphan Nuclear Receptors in Proliferation, Apoptosis and Fuel Utilization Across Tissues

Jacob A. Herring 1,2,†, Weston S. Elison 1,† and Jeffery S. Tessem 1,*

1 Nutrition, Dietetics and Food Science Department, Brigham Young University, Provo, UT 84602, USA; herrin06@gmail.com (J.A.H.); weston.elison@gmail.com (W.S.E.)
2 Microbiology and Molecular Biology Department, Brigham Young University, Provo, UT 84602, USA
* Correspondence: Jeffery_tessem@byu.edu; Tel.: +1-801-422-9082
† These authors contributed equally to this work.

Received: 1 October 2019; Accepted: 30 October 2019; Published: 1 November 2019

Abstract: The Nr4a family of nuclear hormone receptors is composed of three members—Nr4a1/Nur77, Nr4a2/Nurr1 and Nr4a3/NOR1. While currently defined as ligandless, these transcription factors have been shown to regulate varied processes across a host of tissues. Of particular interest, the Nr4a family impinge, in a tissue dependent fashion, on cellular proliferation, apoptosis and fuel utilization. The regulation of these processes occurs through both nuclear and non-genomic pathways. The purpose of this review is to provide a balanced perspective of the tissue specific and Nr4a family member specific, effects on cellular proliferation, apoptosis and fuel utilization.

Keywords: Nr4a1; Nr4a2; Nr4a3; nuclear hormone receptors; metabolism; fuel utilization; proliferation; apoptosis

1. Introduction

The Nr4a family consists of three members, Nr4a1 (Nur77/TR3/NGFI-B), Nr4a2/Nurr1 (TINUR/NOT) and Nr4a3/NOR1 (MINOR/CSMF). The three members have a high degree of sequence homology, with each containing a ligand-independent activation function-1 domain, transactivation domain necessary for transcriptional activity and cofactor binding, a DNA binding domain and a ligand binding domain containing a ligand-dependent AF-2 transactivation domain [1–3]. While currently defined as orphaned receptors with no known endogenous ligand, recent reports suggest that the Nr4a family’s transcription factor function may be regulated through binding unsaturated fatty acids in the ligand binding domain [4–6].

The Nr4a family binds directly as monomers or homodimers to promoters of target genes that contain the NBRE (NGFIB Response Element-AAAGGTCA) motif [7]. The Nr4as can also form heterodimers and bind to the NuRE (Nur Response element-AAT(G/A)(C/T)CA) [8,9]. Finally, Nr4a1 and Nr4a2 have been shown to forms dimers with retinoid X receptors and bind to the DR5 elements [10,11]. While there is a high degree of similarity between the three family members, the different members have differing affinity for co-factors and response elements, thus giving specificity to each [12].

The Nr4a family is widely expressed across various tissues [13]. The family was first discovered in the nervous system [14–17]. Nr4a’s have been shown to be critical in the hematopoietic system [18], adipose tissue [19], liver [20], muscle [21] and β-cells [22], among other tissues [23,24]. In these tissues, the function of Nr4a family members fall into one of two categories. The majority of Nr4a activity is due to direct activation or repression of transcriptional target expression. Interestingly, a growing
body of information is demonstrating a direct non-genomic role of Nr4a’s through interaction with binding partners [25].

While the Nr4a’s are associated with various cellular processes, three are of particular interest. The Nr4a’s, across various tissue types, impinge on cellular proliferation, apoptosis and fuel utilization. These pathways are intimately connected. The cell’s ability and choice of macronutrients as a fuel source and their ability to utilize these molecules, greatly affects proliferation and cell survival. The type of metabolic pathways and choice of fuel oxidation is tightly coordinated with a cell’s ability to proliferate. Similarly, defective fuel utilization pathways or lack of oxidizable macronutrients, can impinge on apoptosis. Finally, signals that induce cell proliferation and apoptosis are in direct opposition to each other. This review will focus on the genomic and non-genomic Nr4a targets that allow for modulation of proliferation, apoptosis and fuel utilization.

2. Proliferation

The Nr4a subfamily is known to regulate cellular proliferation in a tissue dependent manner. Key genes shown to be regulated by Nr4a’s include cyclins, cyclin dependent kinases and other ancillary cell cycle genes. Due to this, Nr4a1, Nr4a2 and Nr4a3 are potential therapeutic targets in many cancers, however their specific roles vary between tissues and among tumors from the same organ. The genes that have been shown to be transcriptionally regulated by the Nr4a’s that are essential for cellular proliferation are summarized in Table 1.

| Tissue/Cell Line | Nr4a1 | Nr4a2 | Nr4a3 |
|------------------|-------|-------|-------|
| Liver | | | |
| Primary Hepatocytes (Partial Hepatectomy) | NF-κB [25]; STAT3 [26]; Cyclin B1 [25]; Cyclin d1 [25]; Cyclin E1 [26]; Cdk4 [26]; Cdk2 [26] | | Cyclin D1 [27]; Cyclin El [27]; VCam1 [27]; PCNA; [27] |
| Hepatic Stellate Cells | | ERK1/2 [28,29]; p38 [28,29]; JNK1 [28] | |
| Muscle | | | |
| Primary Vascular Smooth Muscle | STAT3 [30]; Pim-1 [30]; NFAT [30]; Cyclin D1 [30,31]; PCNA [30,31]; p27Kip1 [32,33] | Cyclin D1 [35–37]; Cyclin D2 [35]; PCNA [37]; | |
| Primary Ventricularmyocytes | ERK1/2 [38]; AKT [38]; | | |
| B-cell | | | |
| Ins-1 832/13 Cells | Cyclin E1 [22]; E2F1 [22]; Ube2c [22]; Cdk5r1 [39]; p21cip1 [22]; pRB [30] | | |
| Immune | | | |
| Primary T Cells | | | |
| Primary Dendritic Cells | | | |
| Macrophage; Dendritic Progenitor Cells | | | |
| Cancer | | | |
| Lung Cancer - H157 Cells | | | |
| Cervical Cancer - HeLa Cells | | | |
| Breast Cancer - MDA-MB-231 Cells | Cyclin D2 [44]; E2F1 [44]; JNK1 [45]; c-Jun [45]; Cyclin D1 [45] | | |
| Acute Myeloid Leukemia-Mouse Models | c-Jun [18]; JunB [18]; CEBPα [46]; myc [46]; STAT1 [46]; IL-6 [46]; ERK1/2 [46]; PKB/AKT [46] | CEBPα [46]; myc [46]; STAT1 [46]; IL-6 [46]; ERK1/2 [46]; PKB/AKT [46] | c-Jun [18]; JunB [18]; CEBPα [46]; myc [46]; STAT1 [46]; IL-6 [46]; ERK1/2 [46]; PKB/AKT [46] |
| Acute Myeloid Leukemia–Kusami-1 Cells | c-Myc [47,48]; Bcl2 [47,48]; CBFα2T3 [47]; CSF1R [47]; PU.1 [47]; TGF-B [46]; p57 [46] | Myc [48]; Bcl2 [48]; TGF-B [48]; p57 [48] | |

Table 1. Genes regulated by the Nr4a’s that are associated with cellular proliferation, defined by tissue of interest. References are given for each gene.
Table 1. Cont.

| Tissue/Cell Line          | Nr4a1                          | Nr4a2                          | Nr4a3                          |
|---------------------------|--------------------------------|--------------------------------|--------------------------------|
| Endothelium               |                                |                                |                                |
| Primary Human Umbilical   | Cyclin A [49]; Cyclin D1 [49]; |                                |                                |
|   Umbilical Vein Endothelial Cells | PCNA [49]; E2F [49]          |                                |                                |
| Intestine                 |                                |                                |                                |
| Intestinal Epithelium -   | p21Cip1 [50]                   |                                |                                |
|   IEC-6 Cells             |                                |                                |                                |
| Uterus                    |                                |                                |                                |
| Leiomyoma Smooth Muscle   | TGFβ3 [51]; SMAD3 [51];        | TGFβ3 [51]; SMAD3 [51];         | TGFβ3 [51]; SMAD3 [51];         |
|   Cells                   | collagen genes 1A1, 6A1, 6A2, 16A1 [51] | collagen genes 1A1, 6A1, 6A2, 16A1 [51] | collagen genes 1A1, 6A1, 6A2, 16A1 [51] |

2.1. Liver

Liver tissue has a remarkable ability to regenerate. Controlled cell proliferation is key in this process to regenerate tissue without becoming malignant. Hepatic stellate cell proliferation has also been identified as an issue in liver fibrosis. In both situations the Nr4a subfamily is a regulatory factor.

2.1.1. Anti-Proliferation

When subjected to partial hepatectomy Nr4a1 deficient mice generated by homologous recombination showed increase in NF-κB and STAT3 protein levels which in turn induced Cyclin B1, Cyclin D1, Cyclin E1, Cdk4 and Cdk2 expression within 24 h, demonstrating that Nr4a1 limits regeneration in hepatocytes [26]. It is important to note, however, that recent findings have shown that the Nr4a1 knock out mouse used in this study (and others) expresses the N-terminal domain of Nr4a1 and that this is sufficient to bind and stabilize HIF1α [52]. While no change in hepatocyte proliferation was demonstrated in this study, it does emphasize the need to validate these results in the floxed Nr4a1 model. In the hepatic stellate cell HSC-T6 cell line Nr4a2 inhibition by siRNA led to increased cell proliferation and decreased phosphorylation of the MAPK pathway members ERK1/2, p38 and JNK [28]. This result was supported by a marked increase in ERK1/2 and p38 phosphorylation observed in HSC-T6 cells overexpressing Nr4a2, along with decreased proliferation [29].

2.1.2. Pro-Proliferation

While Nr4a1 and Nr4a2 inhibit proliferation in liver tissues, Nr4a3 promotes proliferation in both hepatocytes and hepatic stellate cells. Mice treated with Nr4a3 shRNA were subjected to partial hepatectomy. Decreased expression of Cyclin D1, Cyclin E1, VCAM1 and PCNA were observed, as well as lower liver weight. Overexpression of Nr4a3 increased expression of these same genes. Chromatin immunoprecipitation (ChIP) revealed that Nr4a3 directly interacts with the Cyclin D1 promoter, demonstrating that it is a direct Nr4a3 target in hepatocytes [27]. In hepatic stellate cells TGF-β1 was sufficient to drive activation and proliferation. TGF-β1 was observed to increase expression of Nr4a3 and Nr4a3 inhibition impaired primary hepatic stellate cell proliferation, demonstrating Nr4a3’s role in TGF-β1 mediated hepatic stellate cell activation and proliferation [53]. As observed with hepatocytes, the Nr4a subfamily has opposing roles in controlling proliferation which may assist in balancing healthy benign growth.

2.2. Muscle

In smooth and cardiac muscle, proliferation is often associated with hypertrophy and disease pathogenesis such as atherosclerosis, restenosis and heart disease. Again, we see Nr4a’s opposing roles in regulating this process.
2.2.1. Anti-Proliferation

Vascular smooth muscle cells (VSMCs) have been used to study the Nr4a role in smooth muscle. VSMCs derived from pulmonary artery and saphenous vein, PDGF, 5-HT or stress were shown to cause proliferation. When Nr4a1 was overexpressed, it inhibited proliferation by blocking the STAT3/Pim-1/NFAT pathway members which decreased Cyclin D1 and PCNA expression [30–32]. Nr4a1 knock down increased stress induced proliferation and VSMCs from Nr4a1 deficient mice had increased proliferation [31,32]. Nr4a1 expression was increased in VSMCs treated with LDL-activated macrophages. Nr4a1 overexpression lead to lower proliferation rates, less tunica intima growth and induction of p27<sub>Kip1</sub>, all of which ultimately blocked VSMC proliferation induced vessel narrowing [33]. In cardiomyocytes, Nr4a1 was found to block proliferation induced by neuropeptide Y which has been linked to cardiac hypertrophy [54].

Nr4a2 has a similar effect in neonatal tunica intima VSMCs as Nr4a1 does in other VSMCs. Nr4a2 knock down increased proliferation, while overexpression decreased proliferation by increasing p27<sub>Kip1</sub> expression [34]. Nr4a2 also inhibits proliferation in cardiac myocytes. Isoproterenol has been found to increase cardiomyocyte proliferation and when Nr4a2 was overexpressed isoproterenol stimulated proliferation was decreased. The decreased proliferation was due to Nr4a2 mediated increases in DUSP2 and DUSP14 expression which decreased ERK1/2 and AKT phosphorylation [38]. Together, Nr4a1 and Nr4a2 protect against cardiac hypertrophy and vessel narrowing due to stress and other causes such as atherosclerosis.

2.2.2. Pro-Proliferation

Nr4a3 again plays a counter role to Nr4a1 and Nr4a2 in VSMCs. PDGF and hypoxia induce Nr4a3 in VSMCs [35,36]. Nr4a3 promotes proliferation by inducing Cyclin D1, Cyclin D2 and PCNA, which effect was lost with siNr4a3 treatments [35–37]. While Nr4a1 and Nr4a2 are protective against hypertrophy and excess muscle tissue growth, Nr4a3 promotes proliferation. This proliferation may be beneficial in situations but in COPD induced hypoxia it is implicated in causing pulmonary hypertension [36].

2.3. β-Cell

Pro-Proliferation

Nr4a1 and Nr4a3 are both pro-proliferative in the β-cell. As β-cell loss and dysfunction are key aspects of diabetes pathology, β-cell proliferation would enable islet transplants and restored insulin secretion. Nkx6.1, a key β-cell transcription factor upregulates Nr4a1 and Nr4a3 expression. Nr4a1 and Nr4a3 promote proliferation by increasing E2F1 which increases Cyclin E1 concentrations as well as by increasing Ube2c levels which degrades p21<sup>Cip1</sup> [22]. Cdk5r1 expression was also increased and is necessary for Nr4a1 and Nr4a3 driven β-cell proliferation, by increasing pRb phosphorylation and allowing E2F1 mediated increases in cell cycle gene expression [39].

2.4. Immune System

The Nr4a’s have been extensively studied in the immune system. This subfamily plays an important role in regulating various immune cell types, in particular T cells. It is important to note, again, that many of these studies were completed using the Nr4a1 knock out animal that expresses NTD of Nr4a1, which has been shown to stabilize HIF1α [52]. Some of the observed phenotypes of this mouse, particularly in the immune system, have not been found in the floxed Nr4a1 mice, that result in complete gene deletion. This mouse was often used in studies of acute myeloid leukemia (AML)
2.4.1. Pro-Proliferation

The development of a Nr4a1 floxed, Nr4a2 floxed and Nr4a3 deficient mouse as a triple knockout of the Nr4a’s showed their essential role in immune system regulation. These mice die within 21 days of birth with systemic autoimmunity, decreased Treg populations and decreased peripheral T cell proliferation [55]. They have also been found relevant individually in various immune cells types. In cultured neutrophils, Nr4a2 knock down decreases cell viability [56]. Nr4a3 knock down in mouse dendritic cells presents with decreased functionality, including decreased stimulation of T cell proliferation, which is a key step in the adaptive immune response [57].

2.4.2. Anti-Proliferation

Nr4a1 appears to be a negative regulator of T cell proliferation. CD8+ T cell proliferation was inhibited by Nr4a1, through binding to the Irf4 promoter and inhibiting transcription and ultimately Irf4’s proliferative effects in T cells [40]. Nr4a1 knock down also increased dendritic cell function and T cell proliferation to the NF-kB-dependent inflammatory response [41]. While Nr4a3 promotes T cell proliferation through dendritic cells, mice with bone marrow transplanted from Nr4a3 deficient mice have more granulocyte-macrophage precursors and macrophage and dendritic cell progenitors, which is linked to increased plaque formation in atherosclerosis. Nr4a3 deficiency increased RUNX1 expression, a key transcription factor that promotes myeloid progenitor proliferation. Nr4a3 overexpression in turn decreased RUNX1 expression [42].

2.5. Cancer

Just as the Nr4a family members has different functions in different tissues, they behave differently in cancers of various origins. For some tumors the Nr4a’s promote proliferation and in others they inhibit it, making modulation of these transcription factors a possible therapeutic target. Angiogenesis is also linked to the Nr4a subfamily, making it another target to limit tumor growth.

2.5.1. Promotes Proliferation

Nr4a1 and Nr4a2 promote lung cancer growth. H460 and Calu-6 cells overexpressing Nr4a1 had greater BrdU incorporation and Nr4a1 knockdown inhibited H460 cell growth [58]. SPC-A1 and H1299 cells had decreased proliferation when Nr4a1 was knocked down [59]. Nr4a2 knockdown in H157 cells blocked drug induced proliferation, while increased Nr4a2 expression correlated with increased Cyclin D1 expression [43]. Interestingly, Nr4a3 knockdown increased BrdU incorporation, tumor weight and decreased TUNEL positive cells in BRE-AS1 expressing H1299 cells [60]. This data suggests that while Nr4a1 and Nr4a2 increase lung cancer proliferation, Nr4a3 has an inhibitory effect.

Nr4a1 has also been specifically identified to induce proliferation in colorectal cancer, renal cancer, medulloblastomas and thyroid cancer. Two groups showed that Nr4a1 knock down in HCT116 colorectal cancer cells decreased growth and viability [61,62]. Nr4a1 knock down decreased SW620 colony formation, while Nr4a1 overexpression had the opposite effect [63]. Treatment of RKO cells with the Nr4a1 agonist DIM-C-pPhOCH3 lead to decreased proliferation, in contrast with finding with other cell lines [64]. ACHN and 786-O renal cell lines showed that the Nr4a1 antagonists DIM-C-pPhOH and DIM-C-pPhCO2Me decreased cell numbers in a dose dependent manner and decreased ACHN xenograft size, suggesting that Nr4a1 also promotes renal cancer proliferation [65]. Nr4a1 overexpression increased medulloblastoma cell growth and viability, while Nr4a1 knock down decreased proliferation [66]. TT cells, a medullary thyroid carcinoma line, had decreased proliferation when Nr4a1 was knocked down [67].

Just as in the pancreatic β-cells, the Nr4a1’s promote proliferation in pancreatic cancer lines. Nr4a1 knockdown in Panc1 cells had decreased survival and Panc1, MiaPaCa-2 and L3.6pl cell lines treated with the Nr4a1 antagonist DIM-C-pPhOH presented with decreased proliferation [68]. Nr4a2 knock down in BxPC-3 pancreatic cancer cells had decreased cell growth and colony formation [69]. Nr4a2
overexpression increase HTB-52 hepatocellular carcinoma proliferation [70]. Nr4a1 knock down in HeLa cells causes decreased viability and increased growth with Nr4a3 overexpression [71,72]. Nr4a1 is regulated by Pin1 in HeLa cells to express Cyclin D2 and E2F1 and drive proliferation [44]. MCF10A salivary gland cancer cells and mouse submandibular gland cells overexpressing Nr4a3 also showed increased proliferation [73]. Taken together, these data clearly demonstrate a subset of cancers in which Nr4a’s induce proliferation. While this data shows how the Nr4a’s are important for the growth of many cancers, there are many where the reverse is true.

2.5.2. Inhibits Proliferation

The roles of Nr4a1 and Nr4a3 have been studied extensively in AML, where they have similar function. Nr4a1 and Nr4a3 deficient mice develop AML with extensive myeloid cell proliferation due to decreased c-Jun and JunB expression [18]. Nr4a1 floxed and Nr4a3 deficient mice created a less severe AML phenotype but still showed increased hematopoietic stem cell proliferation and decreased bone marrow cellularity. In this state CEBPα, an AML tumor suppressor, was down regulated and Myc genes, STAT1, inflammatory proliferation genes like IL-6 and phosphorylation of PKB/AKT and ERK1/2 all increased [46]. Another study used both Nr4a1−/− Nr4a3−/− and Nr4a1+/+ Nr4a3−/− mice, which increased neutrophil and monocyte proliferation, as well as an increased the BrdU incorporation level in hematopoietic stem cells, multipotent progenitor cells and myeloid progenitors [74]. These studies show that loss of Nr4a1 and Nr4a3 results in impaired immune regulation as well as AML progression.

Studies have further examined the roles of Nr4a1 and Nr4a3 in AML cell lines and other immune cell cancers. Nr4a1 downregulates proliferation associated genes such as c-MYC, BCL2, CBFA2T3 and CSF1R and the myeloid transcription factor PU.1 in Kasumi-1 cells [47]. Nr4a1 and Nr4a3 overexpression decreased Kasumi-1 proliferation and cell viability. Analysis showed that Myc and Bcl2 were down regulated by Nr4a1 and Nr4a3 while TGF-B was upregulated, increasing p57 levels [48]. The pharmacological compounds DHE and ALP are sufficient to block AML tumor growth by inducing Nr4a expression and down regulating c-Myc [75]. Nr4a3 overexpression decreased SuDHL4 B cell line proliferation and xenograph growth. Validating this, Nr4a3 knock down increased cell viability of the U2932 and SuDHL4 cell lines [76]. The observed AML phenotypes in multiple Nr4a knockout mice draws a strong tie to their role in the immune system these genes play and, in a manner, that none of the other cancer tissues can quite match, making this a strong area for continued research.

In addition to their role of inhibiting proliferation in hematopoietic based malignancies Nr4a1 overexpression in UM-UC-3 bladder cancer cells decreased androgen stimulated proliferation, while Nr4a1 knockdown increased growth [77]. Similarly, Nr4a1 overexpression in Ishikawa cells, an endometrial cancer line, decreased proliferation, while Nr4a1 knock down increased proliferation [78]. These data clearly demonstrate a subpopulation of tumors where Nr4a expression inhibits proliferation.

2.5.3. Varied Results

While the Nr4a subfamily may be clear targets in the malignancies discussed this far, there are a few cancers where their role is conflicting, making them less ideal therapeutic targets. The effects of the Nr4a subfamily on breast cancer proliferation is not consistent. MCF-7, MDA-MB-231 and SKBR3 cell lines had decreased cell number and tumor weigh when treated with the Nr4a1 antagonists DIM-C-pPhCO2Me and DIM-C-pPhCN, as well as with Nr4a1 knock down [79]. MDA-MB-231 cells also have decreased proliferation with Nr4a1 overexpression due to JNK1, c-Jun and Cyclin D1 downregulation [45]. MCF-10A cells had no change in proliferation when overexpressing Nr4a1 and measurements across many breast cancer tumors found Nr4a1 expression to be inconsistent, suggesting that Nr4a1’s role in breast cancer may be tumor specific [80]. MDA-MB-468 and MDA-MB-231 lines also had lower xenograft weights with Nr4a2 knockdown [81].

Nr4a’s role in prostate cancer is also conflicting. Nr4a1 knock down decreased PC3 cell line proliferation [82], DU145 and PC3 cells were also Nr4a3 sensitive, with Nr4a3 overexpression decreasing proliferation and tumor size and Nr4a3 proliferation increasing proliferation [83]. These data suggest
that Nr4a1 is pro-proliferative while Nr4a3 is anti-proliferative. This may be similar to primary tissue where Nr4a1 and Nr4a3 play opposing roles to regulate proliferation.

2.5.4. Angiogenesis

While the Nr4a’s role in tumor proliferation is being studied as a therapeutic target it is also being examined for their role in angiogenesis and endothelial cell proliferation. VEGF-A induces Nr4a1 expression and Nr4a1 overexpression in the absence of VEGF-A is sufficient to induce primary umbilical vein endothelial cell proliferation to the same level of VEGF-A alone. Furthermore, Nr4a1 mutants blocked the VEGF-A mediated proliferation effect. Nr4a1 upregulates Cyclin A, Cyclin D1, PCNA and E2F in vasculature endothelial cells [49]. Histamine and serotonin are both sufficient to induce endothelial cell proliferation, however cells deficient in Nr4a1 are resistant to these treatments [84]. Nr4a1 knockdown decreased VEGF induced DNA synthesis in human umbilical vein endothelial cells and when Nr4a1 was knocked down in the presence of VEGF there were fewer vessels per square millimeter in microscopic analysis, suggesting that VEGF acts through Nr4a1 in angiogenesis [85]. As angiogenesis is vital for a tumor expansion and metastasis, it be a potential target to limit the tumor growth regardless of tissue of origin.

2.6. Other Tissues of Note

2.6.1. Pro-Proliferation

Among all of the tissues included there are a few more to be noted where the Nr4a’s have an effect. In an intestinal ischemia mouse model, the mice treated with the Nr4a2 activator C-DIM12 presented increased Ki67+ cells and better recovery [86]. Nr4a1 knock down in IEC-6 intestinal epithelial cells had decreased proliferation, while overexpression increased proliferation by inhibiting p21CIP1 expression [50]. Nr4a1 also promotes spermatogonium development in human primary Sertoli cells by inducing expression of GDNF [87]. Synoviocyte proliferation is part of the pathogenesis of arthritis. Nr4a2 overexpression increased K4IM synoviocyte proliferation, while Nr4a2 knock down decreased proliferation, indicating Nr4a2 as a possible arthritis regulator [88].

2.6.2. Anti-Proliferation

Knockdown of Nr4a1 and Nr4a2 by in mesenchymal stromal cells increased cell cycle progression and overexpression impeded proliferation by inducing a G1 cell cycle block [89]. Nr4a1 knock down increased NIH3T3 fibroblast cell growth [90]. Overexpression of each of the Nr4a genes decreased leiomyoma smooth muscle cells, part of uterine fibroids, proliferation rate by decreasing TGFβ3, SMAD3 and collagen genes 1A1, 6A1, 6A2 and 16A1 expression [51].

2.6.3. Varied Results

Neural tissue presented mixed results with regards to Nr4a2 and proliferation. Nr4a2 overexpression in primary neural stem cells from the olfactory bulb led to fewer BrdU+ cells but when rat adult hippocampal neural precursors were treated with the Nr4a2 agonist amodiaquine, BrdU incorporation and viability increased [91,92].

These data clearly demonstrate that the Nr4a’s play a critical role in regulating cellular proliferation. The Nr4a’s clearly have a tissue specific effect, where they may induce proliferation in one tissue while inhibiting in another. This suggests differences in chromatin accessibility, either due to changes in binding partner expression, post translational modification or chromatin modifications. These data support the ongoing studies to understand mechanisms by which the Nr4a’s induce or inhibit proliferation as potential therapeutic intervention for various conditions.
3. Apoptosis

The second major function of the Nr4a nuclear hormone receptors is regulating cellular apoptosis. The role of the Nr4a’s in controlling apoptosis is complex and present across several tissues. This section will focus on the role of the Nr4a’s on apoptosis, focusing on transcriptional changes in the intrinsic and extrinsic apoptosis pathways, as well as non-genomic functions of the Nr4a nuclear receptors that impinge on apoptosis. The genes that are transcriptionally regulated by the Nr4a’s that are essential for cellular apoptosis are summarized in Table 2.

Table 2. Genes regulated by the Nr4a’s that are associated with cellular apoptosis, defined by tissue of interest. References are given for each gene.

| Tissue/Cell Line | Nr4a1 | Nr4a2 | Nr4a3 |
|-----------------|-------|-------|-------|
| Liver           |       | DNA-PKcs [93] | ERK1/2 [29]; p38 [29]; Ku80 [93] |
| Muscle          |       | Survivin [95]; CHOP [95] | cIAP2 [94] |
| Primary Vascular Smooth | | WT1 [96]; BCL-2 [96]; SOD1 [96] | |
| B-cell          |       |       | |
| Min6            | Survivin [95]; CHOP [95] | |
| Primary Mouse Islets | WT1 [96]; BCL-2 [96]; SOD1 [96] | |
| Immune          |       |       | |
| T Cells         | Fasl [97] | |
| Cancer          |       |       | |
| Pancreas Cancer – Panc-1, L.3.6pL | TXNDC5 [157] | TRAIL [64]; PDCD1 [64] |
| C57BL/6 Nude mice Colon | TRAIL [64]; PDCD1 [64] | |
| Brain           |       |       | |
| Neurons         | Adcyap1 [98]; Sod1 [98]; C-flar [98] | |
| Umbilical Cord  |       |       | |
| HUC-F2          | Caspace3 [99]; Caspase8 [99] | |
| Kidney          |       |       | |
| Hek293          | TRAPy [100]; Hif1-α [101]; pVHL [101] | Hif1-α [101]; pVHL [101]; PARP-1 [102] |
| Bone            |       |       | Poly-ADP-Ribose [103] |

3.1. Intrinsic Apoptotic Pathway

There are two main methods that regulate apoptosis in mammalian cells. They are the intrinsic pathway or mitochondrial signaled apoptosis pathway and the extrinsic pathway or death-receptor mediated pathway. Both involve amplification of proteolytic cascades which leads to apoptosis [104,105]. The intrinsic pathway is activated by cellular stressors that increase mitochondrial permeability. These stressors are recognized by several internal proteins that signal to the mitochondria. The Bcl-2 family is most commonly used in this interaction. The ratio of pro-apoptotic and anti-apoptotic Bcl-2 proteins regulate the pathway. When pro-apoptotic Bcl-2 proteins accumulate, they translocate to the mitochondria and form pores in the mitochondrial membrane. This causes cytochrome c release, caspase-9 activation and eventual cell death [106–108]. Understanding how the Nr4a receptor family regulate these pathways will be addressed.
3.1.1. Liver

Liver fibrosis is a wound healing response caused by over accumulation of extracellular matrix proteins. This leads to decreased liver function and eventually cirrhosis [109]. Nr4a2 overexpression in HSC decreases liver fibrosis [29]. Nr4a2 regulates ERK1/2 and p38 expression in HSC leading to apoptosis. Rats overexpressing Nr4a2 treated with dimethylnitrosamine, which induces liver fibrosis, are protected from liver damage. Nr4a2 overexpression induces apoptosis in the cirrhotic tissue [29]. This shows that Nr4a2 protects healthy liver tissue from becoming fibrotic while also inducing apoptosis in fibrotic tissue via the ERK1/2 and p38 pathway.

3.1.2. β-Cell

The occurrence of type 2 diabetes is closely linked to the loss of pancreatic β-cells and their function [22,110]. Pancreatic β-cells are sensitive to hyperglycemia and hyperlipidemia, which alter Ca^{2+} concentrations in pancreatic islets, leading to increased endoplasmic reticulum (ER) stress and eventually apoptosis via the intrinsic apoptosis pathway [110,111]. Thapsigargin (TG) and palmitic acid (PA) are known inducers of β-cell ER stress. MIN6 cells and primary C57BL/6J mouse islets treatment with TG and PA caused increases in Nr4a1 and C/EBP homologous protein (CHOP) levels in a time-dependent manner [95]. Nr4a1 overexpression in MIN6 cells and islets increased cell survival rates as measured by MTT, TUNEL assay and Caspase3 cleavage. Survivin protein binds to pro-caspase 3 and prevent Caspase 3 activation, reducing cell death [112]. Nr4a1 directly regulates Survivin expression through promoter binding. Nr4a1 knockdown in MIN6 cells treated with TG and PA caused decreased cellular viability via decreased Survivin expression, leading to increased Caspase3 activation and increased CHOP protein. This suggests that Nr4a1 protects the β-cell and primary islets against ER stress by directly upregulating Survivin and indirectly downregulating CHOP.

Proper β-cell function is central to the pathogenesis of type-2 diabetes mellitus [113–115]. Oxidative stress is commonly found in the β-cells of diabetic patients and prevention of this stress is protective in pancreatic β-cells [116]. MIN6 cells treated with H_{2}O_{2} increases Nr4a1 levels and increased Caspase3 cleavage [96]. Nr4a1 overexpression in MIN6 and primary mouse islets cells protects from reactive oxygen species (ROS) damage and increases cellular viability. Expression experiments determined that Nr4a1 overexpression upregulated anti-apoptotic genes (WT1 and BCL-2) and ROS scavenger genes (SOD1). Genetic analysis showed a NBRE binding sequence in the WT1 promoter, ChIP showed that Nr4a1 directly regulates WT1 expression and WT1 knockdown decreased BCL-2 and SOD1 expression. Therefore, Nr4a1 protects primary islets from ROS by directly altering WT1 expression and indirectly increasing BCL-2 and SOD1 expression.

Nr4a3 expression has recently been shown to correlate with cytokine mediated β-cell death [10]. Nr4a3 was upregulated in Ins-1 cells and human islets cultured with IL-1 β and TNFα. This resulted in increased apoptosis as measured by TUNEL staining, DNA fragmentation and cytochrome c release. Knock down of Nr4a3 impaired cytokine mediated apoptosis and re-expression of Nr4a3 induced apoptosis. Together these data suggest that Nr4a1 is anti-apoptotic and Nr4a3 is pro-apoptotic in the pancreatic β-cells.

3.1.3. Cancer

As previously stated, cytochrome c contributes to apoptosis by initiating the caspase cascade upon its release into the cytosol [117–119]. Nr4a1 knockdown significantly decreased apoptosis in prostate cancer cells. A GFP-Nr4a1 fusion protein was used to track location of Nr4a1 during apoptotic treatment. Nr4a1 translocates from the nucleus to the mitochondria when treated with several apoptotic drugs [120]. Prostate cancer cells treated with leptomycin B, which blocks nuclear export [121] and apoptotic drugs, showed decreased cytochrome c release due to decreased Nr4a1 mitochondrial binding [120]. Interestingly, deletion of the DNA binding domain (DBD) of Nr4a1 had no effect on cytochrome c release. It was determined that a 152-amino acid residue from the
NH₂-terminus and 96 amino acids from the COOH-terminus are critical for Nr4a1 mitochondrial targeting. When Nr4a1 was altered to target the plasma membrane [122] or the ER [123] apoptosis was decreased. Similar experiments were done in rats exposed to ischemia in vivo and in primary melanoma tissue [124,125]. Nr4a1 levels were decreased in primary melanoma tissue, possibly leading to protection from apoptotic treatments. Nr4a1 co-localizes with Bcl-2 in the mitochondria in prostate cancer cells, melanoma cells and gastric cancer cells [125–128] These data confirm that Nr4a1 has extra-nuclear functions, independent of DNA binding, as part of the intrinsic apoptotic pathway to induce cytochrome c release. Furthermore, several studies show that the Nr4a family have significant non-genomic function in the body as described [52,93,100–103,129]. Taken together, this shows that while the Nr4a’s primarily function as genetic regulators they have non-genomic functions that are integral for cellular apoptosis and function. The use of the Nr4a1 floxed mouse and the Nr4a1 full body NTD-Nr4a1 mouse could be leveraged to better determine the non-genomic roles of Nr4a1 [101].

Post-translational modifications (PTMs) alter protein function [130,131]. Phosphorylation of Nr4a1 at Ser351 by Akt blocks mitochondrial targeting in H460 lung cancer cells and BGC-823 gastric cancer cells [127,132,133]. Interestingly, in BGC-823 cells Ser351 phosphorylation blocks both nuclear export of Nr4a1 and mitochondrial targeting of cytosolic Nr4a1. The mitochondrial interaction of Nr4a1 in these cancer cells was independent of its DBD, supporting previous data [120]. However, in BGC-823 cells Akt phosphorylation only occurred on the N-terminus of Nr4a1 [127]. Nuclear phosphorylation of Nr4a1 at Ser105 induces export and mitochondrial targeting [133,134]. Akt phosphorylation of Nr4a1 decreases apoptosis and cytochrome c release. Together, these data show that Nr4a1 is regulated by PTMs and that it is integral for apoptosis in cancer cells.

Acute myeloid leukemia is caused by an increase in immature myeloid progenitors and the emergence of leukemia initiating cells. Properties and structure of these cells makes AML difficult to treat. The Nr4a family control regulation of hematopoietic stem cell development [18]. Nr4a1 and Nr4a3 acute expression is sufficient to decrease cellular viability in Kasumi-1 cell lines in a DNA binding domain dependent manner [48]. Nr4a1 and Nr4a3 have a strong inverse correlation to several MYC target genes in Kasumi-1 cells, including Bcl-2 and TNF [48]. Nr4a1 and Nr4a3 also regulate several different types of lymphoma, including non-Hodgkin’s and B-cell. Human samples from cancer patients were analyzed for the Nr4a family and their downstream targets [135–137]. They found that cytoplasmic localization of Nr4a1 increased overall life expectancy of B-cell lymphoma patients through decreased caspase 3 cleavage and ERK1/2 levels [136]. Furthermore, both Nr4a1 and Nr4a3 levels were decreased in Non-Hodgkin’s lymphoma, as well as FasL and TRAIL proteins, which could result in decreased intrinsic and extrinsic apoptotic signaling. Decreased Nr4a1 showed a significant association with poor cancer-specific survival, suggesting that Nr4a1 could be used as an independent prognostic indicator [135]. In SuDHL4 lymphoma cell lines, Nr4a1 overexpression led to increased cleaved caspase 3/7 levels and Annexin V showing an increase an apoptosis. This increase in apoptosis was caused by increased pro-apoptotic proteins, TRAIL, Bim and Puma, suggesting that Nr4a1 acts as an activator on genes responsible for apoptosis in lymphoma cells [135]. Nr4a3 was also found to bind to p53 and induce apoptosis in breast and lung cancer cells and that high levels of Nr4a3 correlated to better survival in these patients [137]. This shows that Nr4a1 and Nr4a3 controls induction of apoptosis in different lymphoma cells.

3.2. Extrinsic Apoptotic Pathway

The extrinsic pathway begins with attachment of ligands to the extracellular domain of transmembrane proteins [138]. Ligand binding signals the intracellular death domain to bind with its corresponding protein motif. These adaptor proteins have a death effector domain which interacts with the death effector domain of procaspase-8. This interaction activates a death inducing signaling complex which catalyzes procaspase-8. Cleaved caspase-8 activates effector caspases which cause cell death by damaging the nucleus and other internal organelle [139–141].
3.2.1. Muscle

The inhibitor of apoptosis (IAP) family of proteins are critical in the regulation of apoptosis [142,143]. IAPs promote pro-survival signaling pathways and prevent apoptosis by interfering with caspase activity [143]. Nr4a3 overexpression protects vascular smooth muscle cells (VSMC) from apoptotic treatment. Hypoxia and the hypoxia mimetic cobalt chloride increased Nr4a3 levels in VSMC. This regulation was determined to be dose and time dependent. Nr4a3 directly regulates cIAP2 expression in VSMC through an NBRE binding site [94]. Knockdown of cIAP2 removes Nr4a3 driven protection. This shows that Nr4a3 protects VSMC from caspase activity by increasing expression of cIAP2.

3.2.2. Immune System

The Nr4a family also induces apoptosis in certain cell types. This has been well documented in T-cells. Induced apoptosis in A04H5.3 T-cells causes an increase in Nr4a1 RNA and protein expression and Nr4a1 dominant negative mutant was protected from cell death [144]. This was also confirmed in vivo using C57Bl/6 transgenic mice which constitutively expressed wildtype Nr4a1 or the dominant negative mutant. They found that Nr4a1 dominant negative mice had lower levels of thymocytes, mature T cells and decreased tolerance while the constitutively expressed wildtype mice were unable to perform antigen-induced negative selection of the T cells [145,146]. While the direct Nr4a1 target genes are still unknown in T-cells there is a correlation between FasL and Nr4a1 expression [97,147]. This shows a complex regulatory network in the Nr4a family that has not been fully determined.

Macrophage treated with LPS and simvastatin undergo a caspase independent apoptotic pathway [148]. Treating RAW 264.7 cells with farnesyl transferase inhibitors decreased LPS and simvastatin mediated apoptosis, suggestion that farnesyl proteins are responsible for apoptosis [149]. Simvastatin treatment alone gradually increases Nr4a1 mRNA levels overtime. RAW 264.7 cells treated with a dominant negative Nr4a1 showed significantly decreased DNA fragmentation and decreased disruption of mitochondrial membrane potential. This is caused by decreased levels of BAX translocation to the mitochondria in cells treated with farnesyl inhibitors [150]. This data shows that Nr4a1 is crucial for non-caspase driven apoptosis pathway and that Nr4a1 plays a role in mitochondrial membrane potential in RAW 264.7 cells.

T-cells expressing chimeric antigen receptors (CAR) targeting human CD19 have exhibited impressive clinical efficacy against B cell cancers [151]. CAR T-cell have been less effective against solid tumors due to an increase in antigen stimulation and decrease effector function [152]. CAR T-cells with deficiencies in Nr4a1, Nr4a2 and Nr4a3 showed improved tumor cell death and increased effector function [153]. This improvement is caused by downregulation of CD8+ T-cell inhibitory receptors PD-1, TIM3 and CTLA4. This function is important for healthy T-cell formation but it is inhibitory for CAR T-cells and leads to dysfunction and exhaustion. This shows that the Nr4a family plays in important role for CAR T-cell function against solid tumors.

3.2.3. Other

The effect of the Nr4a family over the extrinsic apoptosis pathway is very complex and varies depending on cell type and stimulus. H2O2 treatment is commonly used to measure cellular viability as ROS is sufficient to induce apoptosis [98,154,155]. Treatment of human umbilical cord fibroblast (HUC-F2) with H2O2 for 4 h increased Nr4a1 mRNA levels. Knockdown of Nr4a1 decreased cellular viability by increased activated caspase 3 and 8 levels [99]. Therefore, in HUC-F2 cells Nr4a1 functions in a protective, anti-apoptotic role. Similar data have been seen in several different human cancer cell lines, including Panc-1, L3.6pl, MCF7 and RKO, using both siRNA and 1,1-bis(3′-indolyl)-1-(p-anisyl) methane treatments [68,156,157]. Nr4a1 directly regulates TXNDC5 expression which protects Panc-1 cells from ER-stress mediated apoptosis [157]. In primary colon tumor tissue, Nr4a1 expression levels are elevated [68]. Although, Nr4a1 directly regulates tumor necrosis factor–related apoptosis-inducing ligand (TRAIL) protein and PDCD1 in RKO cells. Nr4a1 knockdown in C57BL/6 nude mice with RKO
cells xenografts had decreased tumor volume and final tumor weight [64]. This shows that Nr4a1 plays an important role across different tissues by protecting cells from apoptosis. These data clearly indicate that the Nr4as play a critical role in regulating apoptosis across several different tissues. There does not appear to be a tissue specific effect of these proteins or consensus across the protein family in response to similar treatment. What we can conclude is that their regulatory network is complicated and more research needs to be done fully illuminate their function in regulating apoptotic pathways and future use for therapeutic treatments.

4. Fuel Utilization

A third major function of the Nr4a nuclear hormone receptors is controlling expression of genes associated with fuel utilization. The function of the Nr4a’s in controlling cellular fuel utilization is a function conserved from C. elegans to man, where studies have shown its function in glucose metabolism, lipid metabolism, TCA cycle and oxidative phosphorylation. This section reviews the role of the Nr4a’s in fuel utilization, focusing on effects in glucose metabolism, lipid metabolism and mitochondrial function. The genes regulated by the Nr4a’s that are essential for fuel utilization are summarized in Table 3.

| Tissue/Cell Lines | Nr4a1 | Nr4a2 | Nr4a3 |
|------------------|-------|-------|-------|
| Liver            |       |       |       |
| Primary Hepatocytes | Fbp1 [20,158]; Bpgm [20]; Pgk1 [20]; Eno3 [20,158,159]; G6pc [20,158,159]; Fbp2 [158]; Glut 2 [158]; Pgc1a [20]; Gyr [20]; PEPCK [159]; PC [159]; Lpl [20]; Ehdahd [20]; SREBP1c [20,160]; FAS [20,160]; Gpam [160]; G6Pase [20]; Lipin1 [59]; Pdk4 [20]; Fbp1 [158]; Eno3 [158,159]; G6pc [158,159]; Fbp2 [158]; Glut 2 [158]; PEPCK [159]; PC [159]; |       |       |
| HepG2            | G6pc [161]; PEPCK [161]; CPT1a [162]; | Fbp1 [158]; |       |
| Muscle           |       |       |       |
| Primary Muscle   | Glut4 [20,163–165]; Pfkm [163]; Pygym [167, Eno3 [20,163,164–168]; Bpgm [166,167]; Pgk1 [166,167]; CD36 [164]; AdipoR2 [164]; UCP2 [164]; UCP3 [164]; NADH-TR [165]; Cox1 [165]; Sdhb [165]; | HK1 [169]; Pck1 [169]; GAPDH [169]; Fgama2 [169]; Eno3 [169]; Pkm [169]; MDH [169]; AST [169]; Pdh [169]; Glut4 [169]; HK2 [169]; Sbd1 [169]; Glys1 [169]; PPARy1A [169]; CRAT [169]; ACSL [169]; ACDH [169]; ECH [169]; 3-KCT [169]; Idh3 [169]; Ogdh [169]; Scs [169]; Sdhb [169]; Fh [169]; Mdh [169]; Atf5 [170]; Uqcr2 [170]; Cox1 [170]; Sdhb [170]; and Ndufb8 [170]; |       |
| Cadiomyocyte     | GPT2 [171]; Glut4 [172]; Pfkm [172]; Pygym [172]; | PGC-1a [21]; PGC-1b [21]; Lipin1a [21]; Pdp1r [21]; Pdp1r [21]; Ucp3 [168]; |       |
| C2C12            | SREBP1c [173]; PGAM2 [172]; Eno3 [173]; Aldol [172]; PHKG1 [172]; |       |       |
| Adipose          |       | Glut4 [174]; Ucp1 [175,176]; |       |
| β-cell           |       |       |       |
| Ins-1 832/13     | Eno1 [177,178]; Eno3 [178]; GAPDH [178]; Pgk [178]; Idh3g [177]; Sdhb [177]; | Eno1 [177]; Idh3g [177]; Sdhb [177]; | Eno3 [179]; |
| MIN-6            | En03 [179] |       |       |
Table 3. Cont.

| Tissue/Cell Lines | Nr4a1 | Nr4a2 | Nr4a3 |
|-------------------|-------|-------|-------|
| Immune            |       |       |       |
| Primary T Cells   |       |       |       |
|                   | Hk2 [180]; Aldoa [180]; Aldoc [180]; Gbe1 [180]; Aplp [180]; Atp5f1 [180]; Atp5b [180]; Cox6a1 [180]; Cox6b2 [180]; Cox7b [180]; Ndufa6 [180]; Ndufa5 [180]; Ndufa8 [180]; Ndufa11 [180]; Dlst [180]; Idh3a [180] | | |
| Macrophages       | Idh2 [181]; Idh3b [181]; Idh3g [181] | | |
| Bone Marrow       | Glut1 [52]; Pdk1 [52] | | |
| Cancer            |       |       |       |
| AML-NB4           | Glut1 [182]; Ldha [182] | | |
| AML-THP1          | Glut1 [182]; Ldha [182] | | |
| AML-Kasumi1       | Eno3 [47] | | |
| Melanoma-MV3      | Tpb [183] | | |
| Colorectal-LS-174T| Acox [184]; Cpt1m [184]; Fabp2 [184]; Fabp4 [184] | | |

4.1. Glucose Metabolism

The *C. elegans* Nr4a ortholog is NHR-6. NHR-6 has preferential binding to promoters associated with glucose metabolism [185]. Similar results have shown that Drosophila Nr4a (DHR38) is essential for carbohydrate metabolism, glycogen storage and ethanol metabolism [186,187]. Finally, animal models of insulin resistance and mismanaged glucose metabolism, such as ob/ob and db/db mice or STZ treated or ZDF rats, demonstrate a significant decrease in Nr4a expression in muscle and adipose tissue [174]. These data demonstrate the intimate link between Nr4a transcriptional activity and glucose metabolism. In this section we will review the role of the Nr4a’s in glucose metabolism across various tissues.

4.1.1. Liver

Given the connection between Nr4a’s and glucose metabolism, the liver is an organ of immense interest. Full body Nr4a1 knock out mice present contradictory findings when comparing liver insulin sensitivity. Nr4a1 knock out mice fed a control diet had improved insulin sensitivity, while mice fed a high fat diet presented impaired insulin sensitivity, as demonstrated by hepatic glucose production rate and glucose infusion rate during euglycemic clamp studies [20]. Expression of the glycolytic genes Bpgm and Pgk1 was upregulated in the liver from high fat fed Nr4a1 knock out mice and expression of G6pc was downregulated, while expression of the gluconeogenic genes Fbp1 and Pgc1a was upregulated. Interestingly, expression of the G6Pase, which allows glucose to be released from hepatocytes, was downregulated in Nr4a1 knock out mice under both feeding regimes [20]. It is important to note, however, that a recent study using Cre/flox mediated Nr4a1 deletion demonstrated that the previously published full body Nr4a1 knock out produces a N-terminal domain only truncated Nr4a1 that is sufficient to interact with and stabilize HIF1α [52]. This report demonstrates that some of the phenotypes previously thought to be due to the genomic effects of Nr4a1 may in fact be due to non-genomic functions. Given this result, it is important to validate many of these findings using this model.

Primary hepatocytes treated with glucagon increase expression of Nr4a1, Nr4a2 and Nr4a3, in a cAMP dependent process [158]. Nr4a1 hepatic overexpression results in increased expression of Fbp1, Eno3, G6pc, Pgc1a and Glut 2 [158]. Similarly, Nr4a2 and Nr4a3 overexpression also induce expression of these target genes, resulting in increased gluconeogenesis. The Nr4a mediated induction of these genes correlates with direct binding of Nr4a1, Nr4a2 or Nr4a3 to NBRE sites in the target gene promoters [158].

A recent study demonstrated a direct connection between Nr4a1 and Gyk [188]. Gyk was shown to inhibit expression of two Nr4a1 liver target genes, Eno3 and ApoA5, demonstrating that increased
levels of Gyk decreased expression of these targets through sequestering Nr4a1. This resulted in decreased Eno3, G6Pase and Fbp1 expression and ultimately decreased circulating blood glucose levels [188]. These results were validated with Gyk overexpression in the STZ treated mice and in db/db mice. HepG2 Nr4a1 overexpression was sufficient to decrease expression of the gluconeogenic enzyme G6pc and PEPCK, while Nr4a1 knock down increased expression of these same target genes [161]. Treatment of mice with the conjugated linoleic acid (CLA) trans-10,cis-12-CLA resulted in increased expression of Nr4a1, Nr4a2 and Nr4a3, as well as increased expression of the gluconeogenic genes G6pc, Eno3, PEPCK and PC [159]. Finally, treating mice with the Nr4a1 agonist Csn-B is sufficient to increase circulating blood glucose levels and induce expression of G6pc and Fbp1 [189]. Together these data demonstrate that Nr4a’s (particularly Nr4a1) plays a critical role in regulating expression of glycolysis and gluconeogenesis in hepatocytes.

4.1.2. Muscle

The Nr4a family directly effects muscle glucose utilization pathways. Chao et al. demonstrated that Nr4a1 is expressed in muscle in response to β-adrenergic signaling and that blocking this signal was sufficient to decrease expression of genes associated with glucose uptake (Glut4), glycolysis (Pfk) and glycogenolysis (Pygm) [163]. Furthermore, Nr4a1 overexpression in C2C12 muscle cells or in electroporated primary muscle cells was sufficient to induce expression of these same gene classes. Finally, Nr4a1 knock out muscle demonstrated downregulation of these genes and luciferase and EMSA demonstrated Nr4a1 binding to the promoter of Glut4 and Eno3 [20]. Subsequent studies from the same group demonstrated that full body Nr4a1 knock out mice fed a high fat diet have impaired glucose tolerance and elevated circulating insulin levels [20]. Their data demonstrated muscular insulin resistance, decreased Glut4 expression, decreased insulin receptor phosphorylation and decreased expression of glycolytic genes such as Eno3, Pgm and Pgm1. Further findings demonstrated that loss of Nr4a1 in muscle significantly impairs myofiber size and regeneration [166,167]. Nr4a1 overexpression or induction with metformin or the Nr4a1 pharmaceutical ligand DIM-C-pPhOH and its derivatives in C2C12 muscle cells increased expression of metabolic genes associated with glucose uptake, glycolysis and glycogenolysis, such as Glut4, PHKG1, PGAM2, Eno3, Aldo1 and Pygm [169]. This study demonstrated enhanced glucose uptake and showed that knock down of Nr4a1 impaired the induction observed with either metformin or DIM-C-pPhOH treatment [172]. Similarly, neonatal rat ventricular myocytes overexpressing Nr4a1 presented with elevated glycolysis, as well as induction of the hexosamine pathway branch through GFPT2 induction, resulting in enhanced O-GlcNAcylation of STIM1, ultimately affecting cardiac performance [171].

Nr4a3 results in similar changes in glucose metabolism gene expression. Muscle specific Nr4a3 overexpression mice fed a control diet presented with decreased epididymal, inguinal, brown and total adipose mass [169]. This corresponded with significantly lower circulating leptin levels. When these mice were fed a high fat diet, the animals had decreased weight gain, adipose mass and circulating blood glucose [169]. Significant upregulation of glycolytic genes in the Nr4a3 overexpressing muscle was observed, including induction of HK1, Pfk-1, GAPDH, Pgam2, Eno3 and Pgm1 [169]. In addition, components of the malate aspartate shuttle, including MDH and AST, were upregulated, as was Pdh, with downregulation of the glycerol phosphate shuttle and decreased NAD+/NADH ratio, indicative of more efficient ATP production [169]. Nr4a3 overexpression in muscle also resulted in increased expression of the glycogenic genes Glut4, HK2, Sbdc1 and Gys1, as well as downregulation of the glycogenolytic gene PPP1R1A [169]. This corresponded with increased muscular glycogen content [170]. Together, these data clearly demonstrate that Nr4a1 and Nr4a3 positively regulate glycolysis and glycogenesis within muscle cells.

4.1.3. Adipose Tissue

Nr4a’s also play an important role in adipose tissue glucose utilization. The insulin sensitizing drugs pioglitazone and troglitazone increase adipose tissue glucose uptake and increase expression
of Nr4a1 and Nr4a3 [174]. Similarly, insulin induces Nr4a expression in the 3T3-L1 adipocytes. Finally, overexpression or knock down of Nr4a3 is sufficient to impair adipocyte glucose uptake and overexpression of Nr4a3 causes increased Glut4 expression and transport to the plasma membrane [174]. Interestingly, human adipose samples from obese subjects prior to bariatric surgery demonstrate significantly elevated expression of Nr4a1, Nr4a2 and Nr4a3 and the expression level drops one year after surgery to levels observed in lean subjects [175]. These data support the hypothesis that Nr4a’s control adipocyte glucose metabolism.

4.1.4. β-cells

Loss of Nr4a1 or Nr4a3 but not Nr4a2, in the 832/13 INS-1 β-cell line decreased expression of the glycolytic gene Eno1 [177]. No changes were observed, however, with Aldoa or Pgk1. Similar results are found in the MIN-6 cell line, where Nr4a1 expression was induced by culturing with palmitate, which increased Eno3 expression [179]. Nr4a1 is induced in β-cells in response to palmitate or oleate exposure [190]. Culturing INS-1 β-cells in the presence of oleate, followed by mass spectrometry to define changes to the β-cell proteome demonstrates downregulation of the glycolytic genes Eno1, Eno3, GAPDH and Pgk1 [178]. These data demonstrate that Nr4a1 and Nr4a3 are sufficient to regulate glycolytic gene expression in the pancreatic β-cell, which impinges on glucose utilization and insulin secretion.

4.1.5. Immune System

Changes in fuel metabolism are essential for immune cell differentiation and clonal expansion. A recent study of T-cell activation demonstrated that Nr4a1 knock out T-cells have greater rates of cellular proliferation [180]. This corresponds with increased basal respiration, maximal respiration, glycolysis and glycolytic capacity. They demonstrated upregulation of genes involved in glycolysis, including Hk2, Aldoa and Aldoc [180]. In addition to inducing glycolytic changes, changes were observed in glycogenesis (Gbe1) and glycogenolysis (Agl) [180]. A previous study demonstrated that loss of Nr4a1 impairs Treg differentiation, which corresponds with decreased glycolytic gene expression [191]. Interestingly, loss of Nr4a1 expression in macrophages impairs glycolysis in the LPS stimulated state [181]. This corresponds with decreased lactate production from anaerobic glycolysis. This shift to glycolytic metabolism during macrophage activation is essential for proper production of proinflammatory cytokines and nitric oxide, which is deregulated in Nr4a1 KO mice, resulting in elevated atherosclerotic plaques. Finally, a floxed Nr4a1 mouse model demonstrated decreased expression of Glut1 and Pdk1 in bone marrow [52]. This model which gives complete Nr4a1 deletion, rather than production of the NTD domain only Nr4a1 emphasizes that Nr4a1 (rather than HIF1α or another Nr4a1-NTD binding partner) regulates expression of glycolytic genes. Currently, however, these data suggest that Nr4a1 impedes glycolytic respiration in T-cells, a critical change during T-cell activation.

4.1.6. Cancer

Similar results are described in acute myeloid leukemia (AML) cells from patients and using the NB4 and THP1 cell lines. AML cells from patients have significantly decreased Nr4a1 expression as compared to healthy donors. siRNA mediated knockdown of Nr4a1 in the NB4 cell line caused increased proliferation, Glut1 and Ldha expression and lactate levels. These data suggest that in AML cells, loss of Nr4a1 results in enhanced glucose uptake and anaerobic glycolysis [182]. Treatment with dihydroergotamine (DHE) is sufficient to induce Nr4a1, Nr4a2 and Nr4a3 expression in AML cell lines. DHE treatment also results in induction of Eno3 expression [75]. Furthermore, ChIP-seq of Nr41 binding in AML cells demonstrates strong binding to promoters of various glycolytic genes, including Eno3 [47]. These data clearly demonstrate Nr4a1 regulating glycolytic gene expression in AML cells.
4.2. Lipid Metabolism

Where glucose metabolism focuses on use and production of fuel in the fed state or short-term fuel storage in the form of glycogen, lipid metabolism focuses on the production and usage of the long-term fuel storage form. The Nr4a’s play a role in liver, muscle and adipose tissue controlling the production and usage of lipids.

4.2.1. Liver

Nr4a1 full body knock outs have increased liver triglycerides, cholesterol and hepatic steatosis in response to high fat feeding [20]. This corresponds with increased even-chain acyl carnitine species, increased hepatic Lpl expression and decreased hepatic Ehhadh expression [20]. Hepatic adenoviral mediated Nr4a1 overexpression decreased circulating triglyceride levels, increased LDL levels and decreased HDL levels [160]. This correlates with significantly decreased expression of SREBP1c, FAS and Gpam. In addition, significant downregulation of lipid metabolism genes is observed with Nr4a1 overexpression [160]. Finally, Nr4a1 or Nr4a2 overexpression increased CPT1a in HEPG2 cells, permitting greater fatty acid mitochondrial translocation [162]. These data suggest that Nr4a1 and Nr4a2 push hepatocytes to greater fatty acid production and utilization.

4.2.2. Muscle

Nr4a1 knock down in C2C12 muscle cells decreases triglyceride hydrolysis, as measured by glycerol release [164]. This corresponds with decreased expression of the genes Glut4, CD36, AdipoR2, UCP2 and UCP3 [164]. Nr4a3 overexpression in muscle increased beta-oxidation. This corresponds with increased CRAT, ACSL, ACDH, ECH and 3-KCT expression, all needed for beta-oxidation [169,170]. Nr4a3 loss in C2C12 cells impairs palmitate oxidation and increases anaerobic glycolysis [21]. This corresponded with decreased expression of PGC-1α, PGC-1β, Lipin1α, Pdp1c and Pdp1r [21]. Conversely, treatment with the β-adrenergic activator formoterol enhances these genes associated with oxidative metabolism, presumably through Nr4a3 activation [21]. These data demonstrate that Nr4a1 and Nr4a3 are necessary for muscle lipid metabolism.

4.2.3. Adipose Tissue

The role of Nr4a’s in adipocytes presents conflicting results. Loss of Nr4a1 in 3T3-L1 preadipocytes does not impair adipogenesis or lipid accumulation [192]. This is in contrast to a second report demonstrating that isoalantolactone, which inhibits Nr4a1 activity, decreases 3T3-L1 lipid accumulation [193] and subsequent studies demonstrating that Nr4a1 is essential for adipocyte progenitor function [194]. Finally, Nr4a1 induces p53 and GATA2 expression, which inhibits SREBP1c and PPARy expression and impairs adipogenesis [173]. Therefore, the current data regarding Nr4a’s and adipogenesis is conflicting.

4.2.4. Cancer

While most of the effects of Nr4a1 are directly linked to gene transcription, Nr4a1 does have non-genomic effects that can impinge on lipid metabolism. In melanoma, Nr4a1 translocates to the mitochondria and stabilize TPβ of the mitochondrial trifunctional protein through direct binding. This binding increasing TPβ activity and increase fatty acid oxidation [183]. Similarly, Nr4a2 induction induces fatty acid oxidation in colorectal cancer [184]. It does this by binding to the promoters and inducing expression of Acox, Cpt1m, Fabp2 and Fabp4.

4.3. Mitochondrial Function

Various studies have shown the direct link between Nr4a’s and mitochondrial production and fuel oxidation. This encompasses transcriptional regulation of components of β-oxidation, TCA cycle
and the ETC. This section focuses on the regulation controlled by the Nr4a’s in various metabolically active tissues.

4.3.1. Liver

Loss of Nr4a1 impedes high fat diet mediated induction of non-alcoholic fatty liver disease [195]. This was shown to be due to a decrease in high fat diet mediated mitochondrial fission, oxidative stress and calcium overload [195]. These findings demonstrated decreased mitochondrial respiration in primary hepatocytes due to exposure to elevated levels of palmitate and through Nr4a1 upregulation.

4.3.2. Muscle

Nr4a1 overexpression in C2C12 cells resulted in increased mitochondria number [167]. The increased expression of TCA and ETC components corresponds with enhanced glucose tolerance. Nr4a1 overexpression in muscle also resulted in increased levels of NADH-TR diaphorase, Cox1 and Sdhb, all of which result in increased mitochondrial activity [165]. In addition, these mice had greater mitochondrial DNA concentrations, suggesting increased mitogenesis. Muscle had increased Pdh phosphorylation, suggesting decreased pyruvate flux (and supported by elevated lactate levels). The muscle presented with increased fatty acid oxidation and a shift from mitochondrial pyruvate metabolism. The mice demonstrated increased muscle glycogen and increased glycogenesis. The Nr4a1 overexpressing animal muscle had greater mitochondrial respiration, increased expression of Complex 1 and ultimately increased muscle strength [165]. Similarly, C2C12 cells and primary muscle with Nr4a1 knock down demonstrated decreased Ucp3 expression [164]. Mice selected for running capacity have elevated Nr4a1 and Nr4a3 expression in soleus and EDL muscle [168]. Muscle samples from these mice had elevated expression of the Nr4a targets CD36 and Ucp3, as well as the ETC components Complex 1, Complex 2, Complex 3, Complex 4 and Complex 5. Nr4a3 overexpression in muscle increases TCA cycle flux. This corresponds with increased expression of Idh3, Ogdh, Scs, Sdhb, Fh and Mdh [169,170]. Increased levels of mitochondrial ETC components are also upregulated in muscle with Nr4a3 overexpression, including Atp5a1, Uqcr2, Cox1, Sdhb and Ndufb8 [170]. Together, the data is very clear that Nr4a1 and Nr4a3 are essential for muscle mitochondrial content and fuel oxidation.

4.3.3. Adipose Tissue

Using HIB-1B brown adipocytes and brown adipose tissue from warmth and cold exposed mice, it was shown that Nr4a1 is induced in response to β-adrenergic signaling. Nr4a1 was shown to directly bind to the promoter of Ucp3 and induce its expression, thus defining a role for Nr4a1 as an effector of brown fat thermogenesis [176]. Further studies demonstrated that Nr4a3 also binds to the Ucp1 promoter and can induce its expression [178]. Together, these data demonstrate a connection between the Nr4a’s, mitochondrial genesis and uncoupling in brown adipose tissue.

4.3.4. β-Cells

Loss of Nr4a1 or Nr4a3 but not Nr4a2, in 832/13 INS-1 β-cells results in impaired mitochondrial respiration [177]. Impaired mitochondrial respiration was observed with Nr4a1 or Nr4a3 deficiency but not Nr4a2 deficiency. Impaired respiration was observed in the Leak, OxPhos and ETS states. Measurements of mRNA and protein demonstrated significant decreases in the TCA and ETC components Idh3g and Sdhb. This resulted in decreased NADH and FADH2 cycling, decreased ATP levels and ultimately decreased glucose stimulated insulin secretion [177]. These data clearly demonstrate that Nr4a1 and Nr4a3 are essential for β-cell mitochondrial respiration.

4.3.5. Immune System

T-cell activation in the absence of Nr4a1 results in increased expression of the ETC components Atp5c1, Atp5f1, Atp5h, Cox6a1, Cox6b2, Cox7b, Ndufa6, Ndufa5, Ndufa8 and Ndufa11 [180].
There were also increased expression of the TCA components Dlst and Idh3a. These Nr4a1 deficient T cells had significantly greater basal and maximal respiration. Loss of Nr4a1 in macrophages impairs mitochondrial respiration in the presence or absence of LPS [181]. This corresponds with decreased mitochondrial numbers in the unstimulated state. Nr4a1 knock out macrophages have increased expression of Idh2, Idh3b and Idh3g in the stimulated state, corresponding with significantly elevated succinate levels. The increased succinate levels (and other TCA organic acids) provide added substrates for enhanced cytokine and nitric oxide production that results in enhanced atherosclerotic lesions [181]. Woronicz, J.D.; Calnan, B.; Ngo, V.; Winoto, A. Requirement for the orphan steroid receptor Nur77 in apoptosis of T-cell hybridomas. *Nature* **1994**, *367*, 277–281, doi:10.1038/367277a0.

5. Concluding Remarks

The Nr4a family of orphan nuclear receptors play critical roles in cellular proliferation, apoptosis and fuel utilization. This occurs in a tissue specific mechanism, with a varied response depending on the tissue of interest. These data demonstrate a tissue specific ability of the Nr4a’s to either enhance proliferation or induce apoptosis. These changes impinge on the energy status of the cell, specifically mitochondrial function. This connection to replication, survival and fuel utilization places the Nr4a’s as a critical pharmaceutical target to treat various human disorders.

The mechanisms of Nr4a action are primarily through transcriptional induction or inhibition. The results acquired using the full body Nr4a1 knock out should be validated, however, using the floxed Nr4a1 knock out mice. As mentioned previously, this model results in complete Nr4a1 deletion, rather than expression of the NTD-Nr4a1 variant. These two models, used in tandem, will allow the genomic and non-genomic Nr4a1 functions to be independently defined.

It is interesting that Nr4a’s play dual roles with the mitochondria. Nr4a’s are essential for mitochondrial biogenesis and enzymatic components of the TCA cycle and electron transport chain, which impinge on fuel utilization. Conversely, Nr4a migration to the mitochondria has the ability to stabilize the mitochondria and inhibit the intrinsic apoptotic pathway. The connection between these two pathways warrants more study.

Future work needs to completely curate the Nr4a transcriptional targets through RNA-seq and ChIP-seq studies. Given the tissue specific differences, this is of high priority. Furthermore, while no endogenous ligands are yet defined, recent studies have begun to define putative endogenous ligands, as well as pharmaceutical agonists and antagonists. Greater exploration into the ability of these to modulate Nr4a function needs to be studies and their effects on various tissues. Finally, PTMs are known to modulate Nr4a family member activity. Greater definition of the types and locations of these PTMs, as well as their effect on proliferation, apoptosis and fuel utilization is needed.

**Author Contributions:** J.A.H., W.S.E. and J.S.T. each contributed to writing of the manuscript. All authors read and approved the final manuscript for publication.

**Funding:** This research was funded by the American Diabetes Association, grant number 1-17-IBS-101 (J.S.T.), by the Diabetes Action Research and Education Foundation, grant number 475 (J.S.T.), by the Beatson Foundation, grant number 2019-003 (J.S.T.) and by a BYU HBLL Student Research Grant (J.A.H.).

**Acknowledgments:** The authors thank the members of the Tessem lab for critical discussion regarding these topics.

**Conflicts of Interest:** The authors declare no conflict of interest.

**Abbreviations**

| Abbreviation | Description |
|--------------|-------------|
| 3-KCT3 | ketoacyl-CoA thiolase |
| 5-HT | 5-hydroxytryptamine |
| ACDH | Acyl-CoA dehydrogenase |
| Acx | acyl-CoA oxidase 1 |
| ACSL | Long-chain-fatty-acid—CoA ligase |
| Adcyap1 | Adenylate Cyclase Activating Polypeptide 1 |
| AdipoR2 | Adiponectin Receptor 2 |
| Abbreviation | Description                                      |
|--------------|--------------------------------------------------|
| AF-2        | Activation function 2                           |
| Agl          | amylo-1, 6-glucosidase, 4-alpha-glucotransferase |
| AKT         | Protein kinase B                                |
| Aldoa       | Aldolase A                                      |
| Aldoc       | Aldolase C                                      |
| Alo1        | D-arabinono-1,4-lactone oxidase                 |
| ALP         | Alprostadil                                     |
| AML         | Acute Myeloid Leukemia                         |
| ApoA5       | apolipoprotein A5                              |
| ATP         | Adenosine triphosphate                          |
| Atp5a1      | ATP synthase F1 subunit alpha                   |
| Atp5c1      | ATP Synthase F1 Subunit Gamma                   |
| Atp5h1      | ATP synthase subunit b                          |
| Atp5h       | ATP Synthase Subunit D                          |
| Bcl-2       | B-cell lymphoma 2                               |
| Bpgm        | Bisphosphoglycerate Mutase                     |
| BrdU        | Bromodeoxyuridine                               |
| cAMP        | Cyclic adenosine monophosphate                  |
| CAR         | chimeric antigen receptors                      |
| CBFA2T3     | CBFA2/RUNX1 Partner Transcriptional Co-Repressor 3 |
| CD36        | Cluster of differentiation 36                  |
| CD8         | Cluster of differentiation 8                    |
| C-DIM12     | 1,1-bis(3'-indolyl)-1-(p-chlorophenyl) methane  |
| Cdk2        | Cyclin-dependent kinase 2                       |
| Cdk4        | Cyclin-dependent kinase 4                       |
| Cdk5r1      | Cyclin-dependent kinase 5 activator 1           |
| CEBPα       | CCAAT Enhancer Binding Protein Alpha            |
| C-flar      | CASP8 And FADD Like Apoptosis Regulator         |
| ChIP        | Chromatin immunoprecipitation                   |
| CHOP        | C/EBP homologous protein                        |
| cIAP2       | Baculoviral IAP repeat-containing protein3      |
| CLACOPD     | Conjugated linoleic acidChronic Obstructive Pulmonary Disease |
| Cox1        | Cyclooxygenase 1                                |
| Cox6a1      | Cytochrome C Oxidase Subunit 6A1                |
| Cox6b2      | Cytochrome C Oxidase Subunit 6B2                |
| Cox7b       | Cytochrome C Oxidase Subunit 7B                 |
| CPT1a       | carnitine palmitoyltransferase 1A               |
| Cpt1m       | Carnitine Palmitoyltransferase 1B               |
| CRAT        | Carnitine O-Acetyltransferase                   |
| CSF1R       | Colony Stimulating Factor 1 Receptor            |
| CSMF        | Chondrosarcoma, Extraskeletal Myxoid, Fused To EWS |
| Csn-b       | Cytosporone B                                   |
| Dlst        | Dihydrolipolysine-residue succinyltransferase component of 2-oxoglutarate dehydrogenase complex |
| DBD         | DNA binding domain                              |
| DHE         | dihydroergotamine                               |
| DIM-C-pPhCN | 1,1-bis(3’-indolyl)-1-(p-cyanophenyl) methane Pin1 |
| DIM-C-pPhCO2Me | 1,1-bis(3’-indolyl)-1-(p-carboxymethylphenyl) methane |
| DIM-C-pPhOCH3 | 1,1-bis(3’-indolyl)-1-(p-anisyl) methane        |
| DIM-C-pPhOH  | 1,1-Bis(3’-indolyl)-1-(p-hydroxyphenyl) methane |
| DNA         | deoxyribonucleic acid                           |
| DNA-Pkcs    | DNA-dependent protein kinase                     |
| DR5         | Death receptor 5                                |
| DUSP14      | Dual specificity protein phosphatase 14         |
| DUSP2       | Dual specificity protein phosphatase 2          |
| E2F         | E2 family of transcription factors              |
| E2F1        | E2 transcription factor                         |
| Abbreviation | Full Name |
|--------------|-----------|
| ECH          | Enoyl-CoA hydratase |
| EDL          | ETS-domain lacking |
| Ehhadh       | Enoyl-CoA Hydratase And 3-Hydroxyacyl CoA Dehydrogenase |
| EMSA         | Electrophoretic mobility shift assay |
| Enol1        | Enolase 1 |
| Enol3        | Enolase 3 |
| ER           | Endoplasmic reticulum |
| ERK1/2       | Extracellular signal-regulated kinases |
| ETC          | Electron transport Chain |
| Fabp2        | Fatty Acid Binding Protein 2 |
| Fabp4        | Fatty Acid Binding Protein 4 |
| FADH2        | Flavin adenine dinucleotide |
| FAS          | apoptosis antigen 1 |
| FASL         | Fas ligand |
| Fabp1        | Fructose-Bisphosphatase 1 |
| Fabp2        | Fructose-Bisphosphatase 2 |
| Fh           | Fumarate hydratase |
| G6Pase       | Glucose 6-phosphatase |
| G6pc         | Glucose-6-Phosphatase Catalytic Subunit |
| GAPDH        | Glyceraldehyde 3-phosphate dehydrogenase |
| GATA2        | GATA-binding factor 2 |
| Gbe1         | 1,4-Alpha-Glucan Branching Enzyme 1 |
| GDNF         | Glial cell line-derived neurotrophic factor |
| GFP          | Green fluorescent protein |
| Glut1        | Glucose transporter 1 |
| Glut2        | Glucose transporter 2 |
| Glut4        | Glucose transporter 4 |
| Gpam         | Glycerol-3-Phosphate Acyltransferase |
| Gyk          | Glycerol kinase |
| Gys1         | Glycogen synthase 1 |
| HDL          | High-density lipoproteins |
| Hif1-α       | Hypoxia Inducible Factor 1 Subunit Alpha |
| HK1          | Hexokinase 1 |
| HK2          | Hexokinase 2 |
| HSC          | Hepatic stellate cells |
| HUC-F2       | Human umbilical cord fibroblast |
| H2O2         | Hydrogen peroxide |
| IAP          | inhibitor of apoptosis |
| Idh3         | Isocitrate dehydrogenase (NAD(+)) 3 catalytic subunit |
| Idh3a        | Isocitrate dehydrogenase (NAD(+)) 3 catalytic subunit |
| Idh3g        | Isocitrate Dehydrogenase (NAD(+)) 3 Gamma |
| IL-1β        | Interleukin 1 Beta |
| IL-6         | Interleukin 6 |
| Irf4         | Interferon regulatory factor 4 |
| JNK          | c-Jun N-terminal kinases |
| JNK1         | c-Jun N-terminal kinase 1 |
| JunB         | Transcription Factor Jun-B |
| Ki67         | Antigen Ki-67 |
| Ku-80        | X-Ray Repair Cross Complementing 5 |
| LdhA         | Lactate dehydrogenase A |
| LDL          | Low-density lipids |
| Lipin1       | Phosphatidate Phosphatase LPIN1 |
| Lpl          | Lipoprotein lipase |
| LPS          | lipopolysaccharide |
| MAPK         | Mitogen-activated protein kinase |
| Mdh          | Malate dehydrogenase |
MIN6  Mouse Insulinoma 6
MINOR  Mitogen-Induced Nuclear Orphan Receptor
mRNA  Messenger RNA
MTT  (3-(4, 5-dimethylthiazolyl-2)-2,5-diphenyltetrazolium bromide
Myc  MYC Proto-Oncogene, BHLH Transcription Factor
NAD+  nicotinamide adenine dinucleotide
NADH  nicotinamide adenine dinucleotide
NADH-TR  nicotinamide adenine dinucleotide tetrazolium reductase
NBRE  Nerve growth factor IB response element
Ndufa11  NADH:Ubiquinone Oxidoreductase Subunit A11
Ndufa5  NADH:Ubiquinone Oxidoreductase Subunit A5
Ndufa6  NADH:Ubiquinone Oxidoreductase Subunit A6
Ndufa8  NADH:Ubiquinone Oxidoreductase Subunit A8
NF-κB  Nuclear factor kappa-light-chain-enhancer of activated B cells
NGFI-B  Nuclear Receptor Subfamily 4 Group A Member 1
NOR1  Nuclear Receptor Subfamily 4 Group A Member 3
NOT  Nuclear Receptor Subfamily 4 Group A Member 2
Nr4a1  Nuclear Receptor Subfamily 4 Group A Member 1
Nr4a2  Nuclear Receptor Subfamily 4 Group A Member 2
Nr4a3  Nuclear Receptor Subfamily 4 Group A Member 3
NTD  N-Terminal Domain
Nur77  Nuclear Receptor Subfamily 4 Group A Member 1
NuRE  NGFIB Response Element-AAAGGTCA
Nurr1  Nuclear Receptor Subfamily 4 Group A Member 2
Ogdh  Oxoglutarate Dehydrogenase
O-GlcNAcylation  O-Linked β-N-acetylglucosamineylation
OxPhox  Oxidative Phosphorylation
p21  Cyclin-dependent kinase inhibitor 1
p27  Cyclin-dependent kinase inhibitor 1B
p38  Mitogen-Activated Protein Kinase 14
p53  Tumor protein p53
PA  Palmitic acid
PARP-1  Poly(ADP-Ribose) Polymerase 1
PC  Pyruvate carboxylase
PCNA  Proliferating cell nuclear antigen
PDCD1  Programmed Cell Death 1
PDGF  Platelet-derived growth factor
Pdh  Pyruvate Dehydrogenase E1 Alpha 1 Subunit
Pdk1  Pyruvate Dehydrogenase Kinase 1
Pdp1c  Pyruvate Dehydrogenase Phosphatase Catalytic Subunit 2
Pdp1r  Pyruvate Dehydrogenase Phosphatase Catalytic Subunit 1
PEFCK  Phosphoenolpyruvate Carboxykinase
Pfk-1  Phosphofructokinase 1
Pim-1  Proto-Oncogene, Serine/Threonine Kinase
PKB  Protein kinase B
PU.1  Hematopoietic Transcription Factor PU.1
GADPH  Glyceraldehyde-3-Phosphate Dehydrogenase
PGAM  Phosphoglycerate Mutase 2
PGC-1α  PPARG Coactivator 1 Alpha
PGC-1β  PPARG Coactivator 1 beta
Pgc1a  PPARG Coactivator 1 Alpha
Fgk1  Phosphoglycerate Kinase 1
PHKG1  Phosphorylase Kinase Catalytic Subunit Gamma 1
Pim1  Peptidylprolyl Cis/Trans Isomerase, NIMA-Interacting 1
Pkm  Pyruvate Kinase M1/2
PPARγ  Peroxisome Proliferator Activated Receptor Gamma
PPP1R1A  Protein Phosphatase 1 Regulatory Inhibitor Subunit 1A
pRB Retinoblastoma protein
PTM Post-translational modifications
PTMs Post-translational modifications
pVHL von Hippel–Lindau tumor suppressor
Pygm Glycogen Phosphorylase, Muscle Associated
RNA Ribonucleic acid
ROS Reactive oxygen species
RUNX1 Runt-related transcription factor 1
Scs Succinate-CoA Ligase ADP-Forming Beta Subunit
Sdhb Succinate Dehydrogenase Complex Iron Sulfur Subunit B
shRNA small hairpin RNA
siRNA small interfering RNA
SMAD3 Mothers against decapentaplegic homolog 3
SOD1 Superoxide dismutase
SREBP1c Sterol Regulatory Element Binding Transcription Factor 1
STAT3 Signal transducer and activator of transcription 3
Stbd1 Starch Binding Domain 1
STZ streptozotocin
TCA Tricarboxylic acid cycle
TG Thapsigargin
TGF-β1 Transforming growth factor beta-1
TGFβ3 Transforming growth factor beta-3
TINUR Transcriptionally-Inducible Nuclear Receptor
TNF Tumor Necrosis Factor
TPβ Hydroxyacyl-CoA Dehydrogenase Trifunctional Multienzyme Complex Subunit Beta
TRAIL TNF-related apoptosis-inducing ligand
TRAPγ TRAP-Complex Gamma Subunit
Treg Regulatory T Cell
TUNEL Terminal deoxynucleotidyl transferase-mediated dUTP nick-end labeling
TXNDC5 Thioredoxin Domain-Containing Protein 5
Ube2c Ubiquitin-conjugating enzyme E2 C
Ucp1 Uncoupling Protein 1
UCP2 Uncoupling Protein 2
UCP3 Uncoupling Protein 3
Uqcr2 Ubiquinol-Cytochrome C Reductase Core Protein 2
VCAM1 Vascular cell adhesion protein 1
VEGF Vascular endothelial growth factor
VEGF-A Vascular endothelial growth factor A
VSMC Vascular smooth muscle cell
WT1 Wilms tumor

References
1. Okabe, T.; Takayanagi, R.; Imasaki, K.; Haji, M.; Nawata, H.; Watanabe, T. cDNA cloning of a NGFI-B/ nur77-related transcription factor from an apoptotic human T cell line. *J. Immunol.* 1995, 154, 3871–3879. [CrossRef]
2. Saucedo-Cardenas, O.; Kardon, R.; Ediger, T.R.; Lydon, J.P.; Conneely, O.M. Cloning and structural organization of the gene encoding the murine nuclear receptor transcription factor, NURR1. *Gene* 1997, 187, 135–139. [CrossRef]
3. Zhang, L.; Wang, Q.; Liu, W.; Liu, F.; Ji, A.; Li, Y. The Orphan Nuclear Receptor 4A1: A Potential New Therapeutic Target for Metabolic Diseases. *J. Diabetes Res.* 2018, 2018, 9363461. [CrossRef] [PubMed]
4. de Vera, I.M.; Giri, P.K.; Munoz-Tello, P.; Brust, R.; Fuhrmann, J.; Matta-Camacho, E.; Shang, J.; Campbell, S.; Wilson, H.D.; Granados, J.; et al. Identification of a Binding Site for Unsaturated Fatty Acids in the Orphan Nuclear Receptor Nur1. *ACS Chem. Biol.* 2016, 11, 1795–1799. [CrossRef] [PubMed]
5. de Vera, I.M.S.; Munoz-Tello, P.; Zheng, J.; Dharmarajan, V.; Marciano, D.P.; Matta-Camacho, E.; Giri, P.K.; Shang, J.; Hughes, T.S.; Rance, M.; et al. Defining a Canonical Ligand-Binding Pocket in the Orphan Nuclear Receptor Nur1. *Structure* 2019, 27, 66.e65–77.e65. [CrossRef]

6. Vinayavekhin, N.; Saghatelian, A. Discovery of a protein-metabolite interaction between unsaturated fatty acids and the nuclear receptor Nur77 using a metabolomics approach. *J. Am. Chem. Soc.* 2011, 133, 17168–17171. [CrossRef]

7. Wilson, T.E.; Fahrner, T.J.; Johnston, M.; Milbrandt, J. Identification of the DNA binding site for NGFI-B by genetic selection in yeast. *Science* 1991, 252, 1296–1300. [CrossRef]

8. Wilson, T.E.; Fahrner, T.J.; Milbrandt, J. The orphan receptors NGFI-B and steroidogenic factor 1 establish monomer binding as a third paradigm of nuclear receptor-DNA interaction. *Mol. Cell Biol.* 1993, 13, 5794–5804. [CrossRef]

9. Maira, M.; Martens, C.; Philips, A.; Drouin, J. Heterodimerization between members of the Nur subfamily of orphan nuclear receptors as a novel mechanism for gene activation. *Mol. Cell Biol.* 1999, 19, 7549–7557. [CrossRef]

10. Close, A.F.; Rouillard, C.; Buteau, J. NR4A orphan nuclear receptors in glucose homeostasis: A minireview. *Diabetes Metab.* 2013, 39, 478–484. [CrossRef]

11. Gissendanner, C.R.; Kelley, K.; Nguyen, T.Q.; Hoener, M.C.; Sluder, A.E.; Maina, C.V. The Caenorhabditis elegans NR4A nuclear receptor is required for spermatheca morphogenesis. *Dev. Biol.* 2008, 313, 767–786. [CrossRef] [PubMed]

12. Forman, B.M.; Umesono, K.; Chen, J.; Evans, R.M. Unique response pathways are established by allosteric interactions among nuclear hormone receptors. *Cell* 1995, 81, 541–550. [CrossRef]

13. Pearen, M.A.; Muscat, G.E. Minireview: Nuclear hormone receptor 4A signaling: Implications for metabolic physiological roles. *Cells* 2019, 8, 1373. [CrossRef]

14. Milbrandt, J. Nerve growth factor induces a gene homologous to the glucocorticoid receptor gene. *Neuron* 1988, 1, 183–188. [CrossRef]

15. Law, S.W.; Conneely, O.M.; DeMayo, F.J.; O’Malley, B.W. Identification of a new brain-specific transcription factor, NURR1. *Mol. Endocrinol.* 1992, 6, 2129–2135. [CrossRef]

16. Ohkura, N.; Ito, M.; Tsukada, T.; Sasaki, K.; Yamaguchi, K.; Miki, K. Structure, mapping and expression of a human NOR-1 gene, the third member of the Nur77/NGFI-B family. *Biochim. Biophys. Acta.* 1996, 1308, 205–214. [CrossRef]

17. Bookout, A.L.; Jeong, Y.; Downes, M.; Yu, R.T.; Evans, R.M.; Mangelsdorf, D.J. Anatomical profiling of nuclear receptor expression reveals a hierarchical transcriptional network. *Cell* 2006, 126, 789–799. [CrossRef]

18. Bookout, A.L.; Jeong, Y.; Downes, M.; Yu, R.T.; Evans, R.M.; Mangelsdorf, D.J. Anatomical profiling of nuclear receptor expression reveals a hierarchical transcriptional network. *Cell* 2006, 126, 789–799. [CrossRef]

19. Bookout, A.L.; Jeong, Y.; Downes, M.; Yu, R.T.; Evans, R.M.; Mangelsdorf, D.J. Anatomical profiling of nuclear receptor expression reveals a hierarchical transcriptional network. *Cell* 2006, 126, 789–799. [CrossRef]

20. Pearen, M.A.; Bensinger, S.J.; Villanueva, C.J.; Wroblewski, K.; Tontonoz, P. Inhibition of adipocyte differentiation by Nur77, Nurrl and Nor1. *Mol. Endocrinol.* 2008, 22, 2596–2608. [CrossRef]

21. Chao, L.C.; Wroblewski, K.; Zhang, Z.; Pei, L.; Vergnes, L.; Ilkayeva, O.R.; Ding, S.Y.; Reue, K.; Watt, M.J.; Newgard, C.B.; et al. Insulin resistance and altered systemic glucose metabolism in mice lacking Nur77. *Diabetes* 2009, 58, 2788–2796. [CrossRef]

22. Chao, L.C.; Wroblewski, K.; Zhang, Z.; Pei, L.; Vergnes, L.; Ilkayeva, O.R.; Ding, S.Y.; Reue, K.; Watt, M.J.; Newgard, C.B.; et al. Insulin resistance and altered systemic glucose metabolism in mice lacking Nur77. *Diabetes* 2009, 58, 2788–2796. [CrossRef]

23. Pearen, M.A.; McCarthy, S.; Raichur, S.; Ryall, J.G.; Lynch, G.S.; Muscat, G.E. The orphan nuclear receptor, NOR-1, a target of beta-adrenergic signaling, regulates gene expression that controls oxidative metabolism in skeletal muscle. *Endocrinology* 2008, 149, 2853–2865. [CrossRef] [PubMed]

24. Pearen, M.A.; McCarthy, S.; Raichur, S.; Ryall, J.G.; Lynch, G.S.; Muscat, G.E. The orphan nuclear receptor, NOR-1, a target of beta-adrenergic signaling, regulates gene expression that controls oxidative metabolism in skeletal muscle. *Endocrinology* 2008, 149, 2853–2865. [CrossRef] [PubMed]

25. Maxwell, M.A.; Muscat, G.E. The NR4A subgroup: Immediate early response genes with pleiotropic physiological roles. *Nucl. Recept. Signal* 2006, 4, e002. [CrossRef]
26. Hu, Y.; Zhan, Q.; Liu, H.-X.; Chau, T.; Li, Y.; Yvonne Wan, Y.-J. Accelerated Partial Hepatectomy–Induced Liver Cell Proliferation Is Associated with Liver Injury in Nur77 Knockout Mice. *Am. J. Pathol.* 2014, 184, 3272–3283. [CrossRef]

27. Liu, Y.; Zhang, J.; Yi, B.; Chen, M.; Qi, J.; Yin, Y.; Lu, X.; Jasmin, J.-F.; Sun, J. Nur77 Suppresses Pulmonary Artery Smooth Muscle Cell Proliferation Through Inhibition of the STAT3/Pim-1/NFAT Pathway. *Am. J. Respir. Cell Mol. Biol.* 2013, 50. [CrossRef]

28. Chen, P.; Li, J.; Huo, Y.; Lu, J.; Wan, L.; Li, B.; Gan, R.; Guo, C. Orphan nuclear receptor NR4A2 inhibits hepatic stellate cell proliferation through MAPK pathway in liver fibrosis. *PeerJ* 2015, 3, e1518. [CrossRef]

29. Chen, P.; Li, J.; Huo, Y.; Lu, J.; Wan, L.; Yang, Q.; Huang, J.; Gan, R.; Guo, C. Adenovirus-mediated expression of orphan nuclear receptor NR4A2 targeting hepatic stellate cell attenuates liver fibrosis in rats. *Sci. Rep.* 2016, 6. [CrossRef]

30. de Waard, V.; Arkenbout, E.K.; Vos, M.; Mocking, A.I.; Niessen, H.W.; Stooker, W.; de Mol, B.A.; Quax, P.H.; Bakker, E.N.; VanBavel, E.; et al. TR3 nuclear orphan receptor prevents cyclic stretch-induced proliferation of venous smooth muscle cells. *Am. J. Pathol.* 2006, 168, 2027–2035. [CrossRef]

31. Arkenbout, E.K.; de Waard, V.; van Bragt, M.; van Achterberg, T.A.; Grimbergen, J.M.; Pichon, B.; Pannekoek, H.; de Vries, C.J. Protective function of transcription factor TR3 orphan receptor in atherogenesis: Decreased lesion formation in carotid artery ligation model in TR3 transgenic mice. *Circulation* 2002, 106, 1530–1535. [CrossRef] [PubMed]

32. Bonta, P.I.; Pols, T.W.H.; van Tiel, C.M.; Vos, M.; Arkenbout, E.K.; Rohlena, J.; Koch, K.T.; de Maat, M.P.M.; Tanck, M.W.T.; de Winter, R.J.; et al. Nuclear Receptor Nurr1 Is Expressed In and Is Associated With Human Restenosis and Inhibits Vascular Lesion Formation In Mice Involving Inhibition of Smooth Muscle Cell Proliferation and Inflammation. *Circulation* 2010, 121, 2023–2032. [CrossRef] [PubMed]

33. Nomiyama, T.; Nakamachi, T.; Gizard, F.; Heywood, E.B.; Jones, K.L.; Ohkura, N.; Kawamori, R.; Conneely, O.M.; Bruegger, D. The NR4A Orphan Nuclear Receptor NOR1 Is Induced by Platelet-derived Growth Factor and Mediates Vascular Smooth Muscle Cell Proliferation. *J. Biol. Chem.* 2006, 281, 33467–33476. [CrossRef] [PubMed]

34. Wang, C.-G.; Lei, W.; Li, C.; Zeng, D.-X.; Huang, J.-A. Neuron-derived orphan receptor 1 promoted human pulmonary artery smooth muscle cells proliferation. *Exp. Lung Res.* 2015, 41, 208–215. [CrossRef] [PubMed]

35. Draney, C.; Hobson, A.E.; Grover, S.G.; Jack, B.O.; Tessem, J.S. Cdk5r1 Overexpression Induces Primary beta-Cell Proliferation. *J. Diabetes Res.* 2015, 2016, 6375804. [CrossRef] [PubMed]

36. Nowyhed, H.N.; Huynh, T.R.; Thomas, G.D.; Blatchley, A.; Hedrick, C.C. Cutting Edge: The Orphan Nuclear Receptor Nr4a1 Regulates CD8+ T Cell Expansion and Effector Function through Direct Repression of Irf4. *J. Immunol.*, 2015, 195, 3515–3519. [CrossRef] [PubMed]

37. Tel-Karthaus, N.; Kers-Rebel, E.D.; Looman, M.W.; Ichinose, H.; de Vries, C.J.; Ansems, M. Nuclear Receptor Nur77 Deficiency Alters Dendritic Cell Function. *Front. Immunol.*, 2018, 9. [CrossRef]

38. Ashraf, S.; Hegazy, Y.K.; Harmancey, R. Nuclear receptor subfamily 4 group A member 2 inhibits activation of ERK signaling and cell growth in response to β-adrenergic stimulation in adult rat cardiomyocytes. *Am. J. Physiol. Cell Physiol.* 2019, 317, C513–C524. [CrossRef]

39. Qin, H.; Liu, Y.; Zhao, Y.; Aono, J.; Jones, K.L.; Heywood, E.B.; Howatt, D.; Binkley, C.M.; Daugherty, A.; Liang, Y.; et al. Deficiency of the NR4A Orphan Nuclear Receptor NOR1 in Hematopoietic Stem Cells Accelerates Atherosclerosis. *Stem Cells* 2014, 32, 2419–2429. [CrossRef]

40. Freire, P.R.; Conneely, O.M. NR4A1 and NR4A3 restrict HSC proliferation via reciprocal regulation of C/EBPα and inflammatory signaling. *Blood* 2018, 131, 1081–1093. [CrossRef]

41. Duren, R.P.; Boudreaux, S.P.; Conneely, O.M. Genome Wide Mapping of NR4A Binding Reveals Cooperativity with ETS Factors to Promote Epigenetic Activation of Distal Enhancers in Acute Myeloid Leukemia Cells. *PLoS ONE* 2016, 11, e0150450. [CrossRef] [PubMed]

42. Boudreaux, S.P.; Ramirez-Herrick, A.M.; Duren, R.P.; Conneely, O.M. Genome-wide profiling reveals transcriptional repression of MYC as a core component of NR4A tumor suppression in acute myeloid leukemia. *Oncogenesis* 2012, 1, e19. [CrossRef] [PubMed]

43. Yin, H.; Lo, J.H.; Kim, J.-Y.; Marsh, E.E.; Kim, J.J.; Ghosh, A.K.; Bulun, S.; Chakravarti, D. Expression Profiling of Nuclear Receptors Identifies Key Roles of NR4A Subfamily in Uterine Fibroids. *Mol. Endocrinol.* 2013, 27, 726–740. [CrossRef]
44. Hedrick, E.; Lee, S.-O.; Kim, G.; Abdelrahim, M.; Jin, U.-H.; Safe, S.; Abudayyeh, A. Nuclear Receptor 4A1 (NR4A1) as a Drug Target for Renal Cell Adenocarcinoma. *PLoS ONE* **2015**, *10*, e0128308. [CrossRef]

45. Deutsch, A.J.A.; Rinner, B.; Pichler, M.; Prochazka, K.; Pansy, K.; Bischof, M.; Fechter, K.; Hatzl, S.; Feichtinger, J.; Wenzl, K.; et al. NR4A3 Suppresses Lymphomagenesis through Induction of Proapoptotic Genes. *Cancer Res.* **2017**, *77*, 2375–2386. [CrossRef]

46. Zhao, D.; Liu, W.; Wang, Q.; Li, Q.; Wang, H.; Wang, J.; Teng, T.; Chen, M.; Ji, A.; Li, Y. New Drug Candidate Targeting the 4A1 Orphan Nuclear Receptor for Medullary Thyroid Cancer Therapy. *Molecules* **2018**, *565*. [CrossRef]

47. Ji, L.; Gong, C.; Ge, L.; Song, L.; Chen, F.; Zhu, H.; Zhou, G. Orphan nuclear receptor Nurr1 as a potential novel marker for progression in human pancreatic ductal adenocarcinoma. *Exp. Ther. Med.* **2016**, *13*, 551–559. [CrossRef]

48. Zhu, B.; Sun, L.; Luo, W.; Li, M.; Coy, D.H.; Yu, L.; Yu, W. Activated Notch signaling augments cell growth in hepatocellular carcinoma via up-regulating the nuclear receptor NR4A2. *Oncotarget* **2017**, *8*. [CrossRef]

49. Llopis, S.; Singleton, B.; Duplessis, T.; Carrier, L.; Rowan, B.; Williams, C. Dichotomous roles for the orphan nuclear receptor NURR1 in breast cancer. *BMC Cancer* **2013**, *13*. [CrossRef]

50. Zhao, D.; Desai, S.; Zeng, H. VEGF stimulates PKD-mediated CREB-dependent orphan nuclear receptor Nurr1 expression: Role in VEGF-induced angiogenesis. *Int. J. Cancer* **2010**, *128*, 2602–2612. [CrossRef]

51. Eger, G.; Papadopoulos, N.; Lennartsson, J.; Heldin, C.-H. NR4A1 Promotes PDGF-BB-Induced Cell Colony Formation in Soft Agar. *PLoS ONE* **2014**, *9*, e109047. [CrossRef] [PubMed]

52. Vacca, M.; Murzilli, S.; Salvatore, L.; Di Tullio, G.; D’Orazio, A.; Lo Sasso, G.; Graziano, G.; Pinzani, M.; Chiappa, M.; Mariani–Costantini, R.; et al. Neuron-Derived Orphan Receptor 1 Promotes Proliferation of Quiescent Hepatocytes. *Gastroenterology* **2013**, *144*, 1518–1529. [CrossRef] [PubMed]

53. Yu, Y.; Cai, Z.; Cui, M.; Nie, P.; Sun, Z.H.E.; Sun, S.; Chu, S.; Wang, X.; Hu, L.; Yi, J.; et al. The orphan nuclear receptor Nur77 inhibits low shear stress-induced carotid artery remodeling in mice. *Int. J. Mol. Med.* **2015**, *36*, 1547–1555. [CrossRef] [PubMed]

54. Wang, C.-g.; Li, C.; Lei, W.; Jiang, J.-H.; Huang, J.-a.; Zeng, D.-x. The association of neuron-derived orphan receptor 1 with pulmonary vascular remodeling in COPD patients. *Int. J. Chronic Obstr. Pulm. Dis.* **2018**, *13*, 1177–1186. [CrossRef] [PubMed]

55. Li, X.; Tai, H.H. Activation of thromboxane A2 receptors induces orphan nuclear receptor Nurr1 expression and stimulates cell proliferation in human lung cancer cells. *Carcinogenesis* **2009**, *30*, 1606–1613. [CrossRef]

56. Chen, H.Z.; Li, L.; Wang, W.J.; Du, X.D.; Wen, Q.; He, J.P.; Zhao, B.X.; Li, G.D.; Zhou, W.; Xia, Y.; et al. Prolyl isomerase Pin1 stabilizes and activates orphan nuclear receptor TR3 to promote mitogenesis. *Oncogene* **2011**, *31*, 2876–2887. [CrossRef]

57. Wu, H.; Bi, J.; Peng, Y.; Huo, L.; Yu, X.; Yang, Z.; Zhou, Y.; Qin, L.; Xu, Y.; Liao, L.; et al. Nuclear receptor NR4A1 is a tumor suppressor down-regulated in triple-negative breast cancer. *Oncotarget* **2017**, *8*. [CrossRef]

58. Zeng, H.; Qin, L.; Zhao, D.; Tan, X.; Manseau, E.J.; Van Hoang, M.; Senger, D.R.; Brown, L.F.; Nagy, J.A.; Dvorak, H.F. Orphan nuclear receptor TR3/Nur77 regulates VEGF-A–induced angiogenesis through its transcriptional activity. *J. Exp. Med.* **2006**, *203*, 719–729. [CrossRef]

59. Zu, G.; Yao, J.; Ji, A.; Ning, S.; Luo, F.; Li, Z.; Feng, D.; Rui, Y.; Li, Y.; Wang, G.; et al. Nur77 promotes intestinal regeneration after ischemia/reperfusion injury by inhibiting the expression of p21 (Waf1/Cip1). *J. Mol. Med.* **2014**, *92*, 551–559. [CrossRef]

60. Koenis, D.S.; Medzikovic, L.; Mos, V.; Boldman, T.J.; van Loenen, P.B.; van Tiel, C.M.; Hamers, A.A.J.; Otermin Rubio, I.; de Waard, V.; de Vries, C.J.M. Nur77 variants solely comprising the amino-terminal domain activate hypoxia-inducible factor-1alpha and affect bone marrow homeostasis in mice and humans. *J. Biol. Chem.* **2018**, *293*, 15070–15083. [CrossRef]

61. Xi, X.; Zhang, S.; Cheng, N.; Ge, S.; Wen, J.; Xiao, J.; Wu, X. Oxidored-nitro domain-containing protein 1 promotes liver fibrosis by activating the Wnt/β-catenin signaling pathway in vitro. *Mol. Mol. Rep.* **2017**, *16*, 5050–5054. [CrossRef] [PubMed]

62. Medzikovic, L.; van Roomen, C.; Baartscheer, A.; van Loenen, P.B.; de Vos, J.; Bakker, E.; Koenis, D.S.; Damanafshan, A.; Creemers, E.E.; Arkenbout, E.K.; et al. Nur77 protects against adverse cardiac remodelling by limiting neuropeptide Y signalling in the sympathoadrenal-cardiac axis. *Cardiovasc. Res.* **2018**, *114*, 1617–1628. [CrossRef] [PubMed]
63. Sekiya, T.; Kashiwagi, I.; Yoshida, R.; Fukaya, T.; Morita, R.; Kimura, A.; Ichinose, H.; Metzger, D.; Chambon, P.; Yoshimura, A. Nr4a receptors are essential for thymic regulatory T cell development and immune homeostasis. *Nat. Immunol.* 2013, 14, 230–237. [CrossRef] [PubMed]

64. Prince, L.R.; Prosseda, S.D.; Higgins, K.; Carlring, J.; Prestwich, E.C.; Ogryzko, N.V.; Rahman, A.; Basran, A.; Falciani, F.; Taylor, P.; et al. NR4A orphan nuclear receptor family members, NR4A2 and NR4A3, regulate neutrophil number and survival. *Blood* 2017, 130, 1014–1025. [CrossRef]

65. Nagaoka, M.; Yashiro, T.; Uchida, Y.; Ando, T.; Hara, M.; Arai, H.; Ogawa, H.; Okumura, K.; Kasakura, K.; Nishiyama, C. The Orphan Nuclear Receptor NR4A3 Is Involved in the Function of Dendritic Cells. *J. Immunol.* 2017, 199, 2958–2967. [CrossRef]

66. Kolluri, S.K.; Bruey-Sedano, N.; Cao, X.; Lin, B.; Lin, F.; Han, Y.H.; Dawson, M.I.; Zhang, X.k. Mitogenic Effect of Orphan Receptor TR3 and Its Regulation by MEKK1 in Lung Cancer Cells. *Mol. Cell. Biol.* 2003, 23, 8651–8667. [CrossRef]

67. Zhu, B.; Yang, J.-R.; Jia, Y.; Zhang, P.; Shen, L.; Li, X.-L.; Li, J.; Wang, B. Overexpression of NR4A1 is associated with tumor recurrence and poor survival in non-small-cell lung carcinoma. *Oncotarget* 2017, 8. [CrossRef]

68. Zhang, M.; Wu, J.; Zhong, W.; Zhao, Z.; Liu, Z. Long non-coding RNA BRE-AS1 represses non-small cell lung cancer cell growth and survival via up-regulating NR4A3. *Blood* 2017, 130, 1014–1025. [CrossRef]

69. Xie, X.; Lin, J.; Liu, J.; Huang, M.; Zhong, Y.; Liang, B.; Song, X.; Gu, S.; Chang, X.; Huang, D.; et al. A novel lncRNA NR4A1AS up-regulates orphan nuclear receptor NR4A1 expression by blocking UPF1-mediated mRNA destabilization in colorectal cancer. *Clin. Sci.* 2019, 133, 1457–1473. [CrossRef]

70. Wu, H.; Lin, Y.; Li, W.; Sun, Z.; Gao, W.; Zhang, H.; Xie, L.; Jiang, F.; Qin, B.; Yan, T.; et al. Regulation of Nur77 expression by β-catenin and its mitogenic effect in colon cancer cells. *Faseb. J.* 2011, 25, 192–205. [CrossRef] [PubMed]

71. Cho, S.D.; Yoon, K.; Chintharlapalli, S.; Abdelrahim, M.; Lei, P.; Hamilton, S.; Khan, S.; Ramaiah, S.K.; Safe, S. Nur77 Agonists Induce Proapoptotic Genes and Responses in Colon Cancer Cells through Nuclear Receptor-Dependent and Nuclear Receptor-Independent Pathways. *Cancer Res.* 2007, 67, 674–683. [CrossRef]

72. Lee, S.O.; Abdelrahim, M.; Yoon, K.; Chintharlapalli, S.; Papineni, S.; Kim, K.; Wang, H.; Safe, S. Inactivation of the orphan nuclear receptor TR3/Nur77 inhibits pancreatic cancer cell and tumor growth. *Cancer Res.* 2010, 70, 6824–6836. [CrossRef]

73. Haller, F.; Bieg, M.; Will, R.; Körner, C.; Weichenhan, D.; Bott, A.; Ishaque, N.; Lutsik, P.; Moskalev, E.A.; Mueller, S.K.; et al. Enhancer hijacking activates oncogenic transcription factor NR4A3 in acinic cell carcinomas of the salivary glands. *Nat. Commun.* 2019, 10. [CrossRef]

74. Ramirez-Herrick, A.M.; Mullican, S.E.; Sheehan, A.M.; Conneely, O.M. Reduced NR4A gene dosage leads to mixed myelodysplastic/myeloproliferative neoplasms in mice. *Blood* 2011, 117, 2681–2690. [CrossRef]

75. Boudreaux, S.P.; Duren, R.P.; Call, S.G.; Nguyen, L.; Freire, P.R.; Narayan, P.; Redell, M.S.; Conneely, O.M. Drug targeting of NR4A nuclear receptors for treatment of acute myeloid leukemia. *Leukemia* 2019, 33, 52–63. [CrossRef]

76. Mizushima, T.; Tirador, K.; Miyamoto, H. Androgen receptor activation: A prospective therapeutic target for bladder cancer? *Expert Opin. Ther. Targets* 2017, 21, 249–257. [CrossRef]
81. Sun, L.; Zhou, R.; Dong, J.; Liu, S.; Jiao, Y.; Wang, L.; Hu, S.; He, P.; Liu, X.; Zhao, X.; et al. Lnc-NA inhibits proliferation and metastasis in endometrioid endometrial carcinoma through regulation of NR4A1. *J. Cell. Mol. Med.* 2019. [CrossRef] [PubMed]

82. Hedrick, E.; Lee, S.-O.; Dodapaneni, R.; Singh, M.; Safe, S. Nuclear receptor 4A1 as a drug target for breast cancer chemotherapy. *Endocr. Relat. Cancer* 2015, 22, 831–840. [CrossRef] [PubMed]

83. Qin, L.; Zhao, D.; Xu, J.; Ren, X.; Terwilliger, E.F.; Parangi, S.; Lawler, J.; Dvorak, H.F.; Zeng, H. The vascular permeabilizing factors histamine and serotonin induce angiogenesis through TR3/Nur77 and subsequently truncate it through thrombospondin-1. *Blood* 2013, 121, 2154–2164. [CrossRef] [PubMed]

84. Liu, L.; Yao, J.; Li, Z.; Zu, G.; Feng, D.; Li, Y.; Qasim, W.; Zhang, S.; Li, T.; Zeng, H.; et al. miR-381-3p knockdown improves intestinal epithelial proliferation and barrier function after intestinal ischemia/reperfusion injury by targeting nurr1. *CellDeathDis.* 2018, 9. [CrossRef]

85. Shan, Z.; Hou, Q.; Zhang, N.A.N.; Guo, L.; Zhang, X.; Ma, Y.; Zhou, Y. Overexpression of oxidored-nitro domain containing protein 1 induces growth inhibition and apoptosis in human prostate cancer PC3 cells. *Oncol. Rep.* 2014, 32, 1939–1946. [CrossRef] [PubMed]

86. Ding, L.-J.; Yan, G.-J.; Ge, Q.-Y.; Yu, F.; Zhao, X.; Diao, Z.-Y.; Wang, Z.-Q.; Yang, Z.-Z.; Sun, H.-X.; Hu, Y.-L. FSH acts on the proliferation of type A spermatogonia via Nur77 that increases GDNF expression in the Sertoli cells. *FEBS Lett.* 2011, 585, 2437–2444. [CrossRef]

87. Mix, K.S.; McMahon, K.; McMorrow, J.P.; Walkenhorst, D.E.; Smyth, A.M.; Gogarty, M.; Petrella, B.L.; Dvorak, H.F.; Gogarty, M.; et al. Orphan nuclear receptor NR4A2 induces synovocyte proliferation, invasion and matrix metalloproteinase 13 transcription. *Arthritis Rheum.* 2012, 64, 2126–2136. [CrossRef] [PubMed]

88. Maijenburg, M.W.; Gilissen, C.; Melief, S.M.; Kleijer, M.; Weijer, K.; ten Brinke, A.; Roelofs, H.; Van Tiel, C.M.; Veltman, J.A.; de Vries, C.J.M.; et al. Nuclear Receptors Nur77 and Nurr1 Modulate Mesenchymal Stromal Cell Migration. *Stem Cells Dev.* 2012, 21, 228–238. [CrossRef] [PubMed]

89. Vergaño-Vera, E.; Díaz-Guerra, E.; Rodriguez-Traver, E.; Méndez-Gómez, H.R.; Solis, Ó.; Pignatelli, J.; Pickel, J.; Lee, S.-H.; Moratalla, R.; Vicario-Abejon, C. Nurr1 blocks the mitogenic effect of FGF-2 and EGF, inducing olfactory bulb neural stem cells to adopt dopaminergic and dopaminergic-GABAergic neuronal phenotypes. *Dev. Neurobiol.* 2014, 75, 823–841. [CrossRef] [PubMed]

90. Kim, J.-i.; Jeon, S.G.; Kim, K.A.; Kim, Y.J.; Song, E.J.; Choi, J.; Ahn, K.J.; Kim, C.-J.; Chung, H.Y.; Moon, M.; et al. The pharmacological stimulation of Nurr1 improves cognitive functions via enhancement of adult hippocampal neurogenesis. *Stem Cell Res.* 2016, 17, 534–543. [CrossRef] [PubMed]

91. Zhu, W.; Cowie, A.; Wasfy, G.W.; Penn, L.Z.; Leber, B.; Andrews, D.W. Bcl-2 mutants with restricted subcellular location reveal spatially distinct pathways for apoptosis in different cell types. *Embo. J.* 1996, 15, 4130–4141. [CrossRef] [PubMed]

92. Goldar, S.; Khaniani, M.S.; Derakhshan, S.M.; Baradaran, B. Molecular mechanisms of apoptosis and roles in cancer development and treatment. *Asian Pac. J. Cancer Prev.* 2015, 16, 2129–2144. [CrossRef] [PubMed]

93. Kim, B.Y.; Kim, H.; Cho, E.J.; Youn, H.D. Nur77 upregulates HIF-alpha by inhibiting pVHL-mediated degradation. *Exp. Mol. Med.* 2008, 40, 71–83. [CrossRef]

94. Strasser, A. The role of BH3-only proteins in the immune system. *Nat. Rev. Immunol.* 2005, 5, 189–200. [CrossRef]

95. Simon, H.U.; Haj-Yehia, A.; Levi-Schaffer, F. Role of reactive oxygen species (ROS) in apoptosis induction. *Apoptosis* 2000, 5, 415–418. [CrossRef] [PubMed]

96. Redzsa-Dutordoir, M.; Averill-Bates, D.A. Activation of apoptosis signalling pathways by reactive oxygen species. *Biochim. Biophys. Acta* 2016, 1863, 2977–2992. [CrossRef]

97. Kudo, N.; Matsumori, N.; Taoka, H.; Fujiwara, D.; Schreiner, E.P.; Wolff, B.; Yoshida, M.; Horinouchi, S. Leptomycin B inactivates CRM1/exportin 1 by covalent modification at a cysteine residue in the central conserved region. *Proc. Natl. Acad. Sci. United States Am.* 1999, 96, 9112–9117. [CrossRef]
100. Leevers, S.J.; Paterson, H.F.; Marshall, C.J. Requirement for Ras in Raf activation is overcome by targeting Raf to the plasma membrane. *Nature* **1994**, *369*, 411–414. [CrossRef]

101. Yu, H.; Kumar, S.M.; Fang, D.; Acs, G.; Xu, X. Nuclear orphan receptor TR3/Nur77 mediates melanoma cell apoptosis. *Cancer Biol. Ther.* **2007**, *6*, 405–412. [CrossRef] [PubMed]

102. Cheng, Z.; Volkers, M.; Din, S.; Avitabile, D.; Khan, M.; Gude, N.; Mohsin, S.; Bo, T.; Truffa, S.; Alvarez, R.; et al. Mitochondrial translocation of Nur77 mediates cardiomyocyte apoptosis. *Eur. Heart J.* **2011**, *32*, 2179–2188. [CrossRef] [PubMed]

103. Zhao, B.X.; Chen, H.Z.; Du, X.D.; Luo, J.; He, J.P.; Wang, R.H.; Wang, Y.; Wu, R.; Hou, R.R.; Hong, M.; et al. Orphan receptor TR3 enhances p53 transactivation and represses DNA double-strand break repair in hepatoma cells under ionizing radiation. *Mol. Endocrinol.* **2011**, *25*, 1337–1350. [CrossRef] [PubMed]

104. Alonso, J.; Galan, M.; Marti-Pamies, I.; Romero, J.M.; Camacho, M.; Rodriguez, C.; Martinez-Gonzalez, J. NOR-1/NR4A3 regulates the cellular inhibitor of apoptosis 2 (cIAP2) in vascular cells: Role in the survival response to hypoxic stress. *Sci. Rep.* **2016**, *6*, 34056. [CrossRef]

105. Yu, C.; Cui, S.; Zong, C.; Gao, W.; Xu, T.; Gao, P.; Chen, J.; Qin, D.; Guan, Q.; Liu, Y.; et al. The Orphan Nuclear Receptor NR4A1 Protects Pancreatic beta-Cells from Endoplasmic Reticulum (ER) Stress-mediated Apoptosis. *J. Biol. Chem.* **2015**, *290*, 20687–20699. [CrossRef]

106. Zong, C.; Qin, D.; Yu, C.; Gao, P.; Chen, J.; Lu, S.; Zhang, Y.; Liu, Y.; Yang, Y.; Pu, Z.; et al. The stress-response molecule NR4A1 resists ROS-induced pancreatic beta-cells apoptosis via WT1. *Cell Signal* **2017**, *35*, 129–139. [CrossRef]

107. Toth, B.; Ludanyi, K.; Kiss, I.; Reichert, U.; Michel, S.; Fesus, L.; Szondy, Z. Retinoids induce Fas(CD95) ligand cell surface expression via RARgamma and nur77 in T cells. *Eur. J. Immunol.* **2004**, *34*, 827–836. [CrossRef]

108. Volakakis, N.; Kadkhodaei, B.; Joodmardi, E.; Wallis, K.; Fanman, L.; Silvaggi, J.; Spiegelman, B.M.; Perlmann, T. NR4A orphan nuclear receptors as mediators of CREB-dependent neuroprotection. *Proc. Natl. Acad. Sci. United States Am.* **2010**, *107*, 12317–12322. [CrossRef]

109. Shimizu, Y.; Miyakura, R.; Otsuka, Y. Nuclear receptor subfamily 4, group A, member 1 inhibits extrinsic apoptosis and reduces caspase-8 activity in H2O2-induced human HUC-F2 fibroblasts. *Redox Rep.* **2015**, *20*, 81–88. [CrossRef]

110. Chen, H.Z.; Wen, Q.; Wang, W.J.; He, J.P.; Wu, Q. The orphan nuclear receptor TR3/Nur77 regulates ER stress and induces apoptosis via interaction with TRAPgamma. *Int. J. Biochem. Cell Biol.* **2013**, *45*, 1600–1609. [CrossRef]

111. Ohkura, N.; Nagamura, Y.; Tsukada, T. Differential transactivation by orphan nuclear receptor NOR1 and its fusion gene product EWS/NOR1: Possible involvement of poly(ADP-ribose) polymerase I, PARP-1. *J. Cell Biochem.* **2008**, *105*, 785–800. [CrossRef] [PubMed]

112. Munnur, D.; Somers, J.; Skalka, G.; Weston, R.; Jukes-Jones, R.; Bhogadia, M.; Dominguez, C.; Cain, K.; Ahel, I.; Malewicz, M. NR4A Nuclear Receptors Target Poly-ADP-Ribosylated DNA-PKcs Protein to Promote DNA Repair. *Cell Rep.* **2019**, *29*, 2028–2036. [CrossRef] [PubMed]

113. Nair, P.; Lu, M.; Petersen, S.; Ashkenazi, A. Apoptosis initiation through the cell-extrinsic pathway. *Methods Enzymol.* **2014**, *544*, 99–128. [CrossRef]

114. Movassagh, M.; Foo, R.S. Simplified apoptotic cascades. *Heart Fail. Rev.* **2008**, *13*, 111–119. [CrossRef]

115. Hotchkiss, R.S.; Strasser, A.; McDunn, J.E.; Swanson, P.E. Cell death. *Indian J. Med. Res.* **2009**, *136*, 1570–1583. [CrossRef]

116. Thomas, H.E.; McKenzie, M.D.; Angstetra, E.; Campbell, P.D.; Kay, T.W. Beta cell apoptosis in diabetes. *Apoptosis* **2009**, *14*, 1389–1404. [CrossRef]

117. Wake, K. Perisinusoidal stellate cells (fat-storing cells, interstitial cells, lipocytes), their related structure in and around the liver sinusoids and vitamin A-storing cells in extrahepatic organs. *Int. Rev. Cytol.* **1980**, *66*, 303–353. [CrossRef]

118. Karaskov, E.; Scott, C.; Zhang, L.; Teodoro, T.; Ravazzola, M.; Volchuk, A. Chronic palmitate but not oleate exposure induces endoplasmic reticulum stress, which may contribute to INS-1 pancreatic beta-cell apoptosis. *Endocrinology* **2006**, *147*, 3398–3407. [CrossRef]

119. Gwiazda, K.S.; Yang, T.L.; Lin, Y.; Johnson, J.D. Effects of palmitate on ER and cytosolic Ca2+ homeostasis in beta-cells. *Am. J. Physiol. Endocrinol. Metab.* **2009**, *296*, E690–E701. [CrossRef]

120. Jaiswal, P.K.; Goel, A.; Mittal, R.D. Survivin: A molecular biomarker in cancer. *Indian J. Med. Res.* **2015**, *141*, 389–397. [CrossRef]
121. Cnop, M.; Welsh, N.; Jonas, J.C.; Jorns, A.; Lenzen, S.; Eizirik, D.L. Mechanisms of pancreatic beta-cell death in type 1 and type 2 diabetes: Many differences, few similarities. *Diabetes 2005*, 54 Suppl. 2, S97–S107. [CrossRef]

122. Steppel, J.H.; Horton, E.S. Beta-cell failure in the pathogenesis of type 2 diabetes mellitus. *Curr. Diab. Rep.* 2004, 4, 169–175. [CrossRef] [PubMed]

123. Laybutt, D.R.; Preston, A.M.; Akerfeldt, M.C.; Kench, J.G.; Busch, A.K.; Biankin, A.V.; Biden, T.J. Endoplasmic reticulum stress contributes to beta cell apoptosis in type 2 diabetes. *Diabetologia* 2007, 50, 752–763. [CrossRef] [PubMed]

124. Tajiri, Y.; Moller, C.; Grill, V. Long-term effects of aminoquinidine on insulin release and biosynthesis: Evidence that the formation of advanced glycosylation end products inhibits B cell function. *Endocrinology* 1997, 138, 273–280. [CrossRef] [PubMed]

125. Cai, J.; Yang, J.; Jones, D.P. Mitochondrial control of apoptosis: The role of cytochrome c. *Biochim. Biophys. Acta* 1998, 1366, 139–149. [CrossRef]

126. Jiang, X.; Wang, X. Cytochrome C-mediated apoptosis. *Annu. Rev. Biochem.* 2004, 73, 87–106. [CrossRef]

127. Huttemann, M.; Pecina, P.; Rainbolt, M.; Sanderson, T.H.; Kagan, V.E.; Samavati, L.; Doan, J.W.; Lee, I. The multiple functions of cytochrome c and their regulation in life and death decisions of the mammalian cell: From respiration to apoptosis. *Mitochondrion* 2011, 11, 369–381. [CrossRef]

128. Li, H.; Kolluri, S.K.; Gu, J.; Dawson, M.I.; Cao, X.; Hobbs, P.D.; Lin, B.; Chen, G.; Lu, J.; Lin, F.; et al. Cytochrome c release and apoptosis induced by mitochondrial targeting of nuclear orphan receptor TR3. *Science* 2000, 289, 1159–1164. [CrossRef]

129. Lin, B.; Kolluri, S.K.; Lin, F.; Liu, W.; Han, Y.H.; Cao, X.; Dawson, M.I.; Reed, J.C.; Zhang, X.K. Conversion of Bcl-2 from protector to killer by interaction with nuclear orphan receptor Nur77/TR3. *Cell* 2004, 116, 527–540. [CrossRef]

130. Chen, H.Z.; Zhao, B.X.; Zhao, W.X.; Li, L.; Zhang, B.; Wu, Q. Akt phosphorylates the TR3 orphan receptor and blocks its targeting to the mitochondria. *Carcinogenesis* 2008, 29, 2078–2088. [CrossRef]

131. Zhan, Y.Y.; Wu, Q. Translocation of orphan receptor TR3 from nuclei to mitochondria induced by staurosorine. *Ai Zheng* 2004, 23, 1593–1598. [PubMed]

132. Sun, Z.; Cao, X.; Jiang, M.M.; Qiu, Y.; Zhou, H.; Chen, L.; Qin, B.; Wu, H.; Jiang, F.; Chen, J.; et al. Inhibition of beta-catenin signaling by non-genomic action of orphan nuclear receptor Nur77. *Oncogene* 2012, 31, 2653–2667. [CrossRef]

133. Gill, G. Post-translational modification by the small ubiquitin-related modifier SUMO has big effects on transcription factor activity. *Curr. Opin. Genet. Dev.* 2003, 13, 108–113. [CrossRef]

134. Bode, A.M.; Dong, Z. Post-translational modification of p53 in tumorigenesis. *Nat. Rev. Cancer* 2004, 4, 793–805. [CrossRef]

135. Han, Y.H.; Cao, X.; Lin, B.; Lin, F.; Kolluri, S.K.; Stebbins, J.; Reed, J.C.; Dawson, M.I.; Zhang, X.K. Regulation of Nur77 nuclear export by c-Jun N-terminal kinase and Akt. *Oncogene* 2006, 25, 2974–2986. [CrossRef]

136. Hirata, Y.; Kiuchi, K.; Chen, H.C.; Milbrandt, J.; Guroff, G. The phosphorylation and DNA binding of the DNA-binding domain of the orphan nuclear receptor NGFI-B. *J. Biol. Chem.* 1993, 268, 24808–24812.

137. Katagiri, Y.; Takeda, K.; Yu, Z.X.; Ferrans, V.J.; Ozato, K.; Guroff, G. Modulation of retinoic signalling through NGF-induced nuclear export of NGFI-B. *Nat. Cell Biol.* 2000, 2, 435–440. [CrossRef]

138. Deutsch, A.J.; Rinner, B.; Wenzl, K.; Pichler, M.; Troppan, K.; Steinbauer, E.; Schwarzenbacher, D.; Reitter, S.; Feichtinger, J.; Terlinding, S.; et al. NR4A1-mediated apoptosis suppresses lymphomagenesis and is associated with a favorable cancer-specific survival in patients with aggressive B-cell lymphomas. *Blood* 2014, 123, 2367–2377. [CrossRef]

139. Fechter, K.; Feichtinger, J.; Prochazka, K.; Unterluggauer, J.J.; Pansy, K.; Steinbauer, E.; Pichler, M.; Haybaeck, J.; Prokesch, A.; Greinix, H.T.; et al. Cytoplasmic location of NR4A1 in aggressive lymphomas is associated with a favourable cancer specific survival. *Sci. Rep.* 2018, 8, 14528. [CrossRef]

140. Fedorova, O.; Petukhov, A.; Daks, A.; Shuvavol, O.; Leonova, T.; Vasilyeva, E.; Aksenov, N.; Melino, G.; Barlev, N.A. Orphan receptor NR4A3 is a novel target of p53 that contributes to apoptosis. *Oncogene* 2019, 38, 2108–2122. [CrossRef]

141. Jin, Z.; El-Deiry, W.S. Overview of cell death signaling pathways. *Cancer Biol.* 2005, 4, 139–163. [CrossRef] [PubMed]

142. Boattigh, K.M.; Salvesen, G.S. Mechanisms of caspase activation. *Curr. Opin. Cell Biol.* 2003, 15, 725–731. [CrossRef] [PubMed]
143. Khosravi-Far, R.; Esposti, M.D. Death receptor signals to mitochondria. *Cancer Biol.* 2004, 3, 1051–1057. [CrossRef] [PubMed]

144. Silke, J.; Meier, P. Inhibitor of apoptosis (IAP) proteins-modulators of cell death and inflammation. *Cold Spring Harb Perspect Biol.* 2013, 5. [CrossRef] [PubMed]

145. Lawlor, K.E.; Feltham, R.; Yabal, M.; Conos, S.A.; Chen, K.W.; Zhan, Y.; Nguyen, T.A.; Hall, C.; et al. XIAP Loss Triggers RIPK3- and Caspase-8-Driven IL-1beta Activation and Cell Death as a Consequence of TLR-MyD88-Induced cIAP1-TRAF2 Degradation. *Cell Rep.* 2017, 20, 668–682. [CrossRef] [PubMed]

146. Calnan, B.J.; Szychowski, S.; Chan, F.K.; Cado, D.; Winoto, A. A role for the orphan steroid receptor Nur77 in apoptosis accompanying antigen-induced negative selection. *Immunity* 1995, 3, 273–282. [CrossRef]

147. Liu, X.; Wang, Y.; Lu, H.; Li, J.; Yan, X.; Xiao, M.; Hao, J.; Alekseev, A.; Khong, H.; Chen, T.; et al. Genome-wide analysis identifies NR4A1 as a key mediator of T cell dysfunction. *Nature* 2019, 567, 525–529. [CrossRef]

148. Kristie, T.M.; Roizman, B. DNA-binding site of major regulatory protein alpha 4 specifically associated with promoter-regulatory domains of alpha genes of herpes simplex virus type 1. *Proc. Natl. Acad. Sci. United States Am.* 1986, 83, 4700–4704. [CrossRef]

149. Kim, Y.C.; Song, S.B.; Lee, M.H.; Kang, K.I.; Lee, H.; Paik, S.G.; Kim, K.E.; Kim, Y.S. Simvastatin induces caspase-independent apoptosis in LPS-activated RAW264.7 macrophage cells. *Biochem. Biophys. Res. Commun.* 2006, 339, 1007–1014. [CrossRef]

150. Kim, Y.D.; Kim, S.G.; Hwang, S.L.; Choi, H.S.; Bae, J.H.; Song, D.K.; Im, S.S. B-cell translocation gene 2 regulates hepatic glucose homeostasis via induction of orphan nuclear receptor Nur77 in diabetic mouse model. *Diabetes* 2014, 63, 1870–1880. [CrossRef]

151. Kim, Y.C.; Song, S.B.; Lee, S.K.; Park, S.M.; Kim, Y.S. The Nuclear Orphan Receptor NR4A1 Is Involved in the Apoptotic Pathway Induced by LPS and Simvastatin in RAW 264.7 Macrophages. *Immune Netw.* 2014, 14, 116–122. [CrossRef] [PubMed]

152. Davila, M.L.; Riviere, I.; Wang, X.; Bartido, S.; Park, J.; Curran, K.; Chung, S.S.; Stefanski, J.; Borquez-Ojeda, O.; Olszewska, M.; et al. Efficacy and toxicity management of 19-28z CAR T cell therapy in B cell acute lymphoblastic leukemia. *Sci. Transl. Med.* 2014, 6, 224ra225. [CrossRef] [PubMed]

153. Schietinger, A.; Greenberg, P.D. Tolerance and exhaustion: Defining mechanisms of T cell dysfunction. *Trends Immunol.* 2014, 35, 51–60. [CrossRef] [PubMed]

154. Chen, J.; Lopez-Moyado, I.F.; Lee, H.; Lio, C.J.; Hempleman, L.J.; Sekiya, T.; Yoshimura, A.; Scott-Browne, J.P.; Rao, A. NR4A transcription factors limit CAR T cell function in solid tumours. *Nature* 2019, 567, 530–534. [CrossRef] [PubMed]

155. Lee, S.O.; Andey, T.; Jin, U.H.; Kim, K.; Singh, M.; Safe, S. The nuclear receptor TR3 regulates mTORC1 signaling in lung cancer cells expressing wild-type p53. *Oncogene* 2012, 31, 3265–3276. [CrossRef]

156. Lee, S.O.; Jin, U.H.; Kang, J.H.; Kim, S.B.; Guthrie, A.S.; Sreevalsan, S.; Lee, J.S.; Safe, S. The orphan nuclear receptor NR4A1 (Nur77) regulates oxidative and endoplasmic reticulum stress in pancreatic cancer cells. *Mol. Cancer Res.* 2014, 12, 527–538. [CrossRef]

157. Ishizawa, M.; Kagechika, H.; Makishima, M. NR4A nuclear receptors mediate carnitine palmitoyltransferase 1A gene expression by the rexinoid HX600. *Biochem. Biophys. Res. Commun.* 2012, 418, 780–785. [CrossRef]

158. Chao, L.C.; Wroblewski, K.; Ilkayeva, O.R.; Stevens, R.D.; Bain, J.; Meyer, G.A.; Schenk, S.; Martinez, L.; Vassar, R.; et al. Skeletal muscle Nur77 expression enhances oxidative metabolism and substrate utilization. *J. Lipid Res.* 2012, 53, 2610–2619. [CrossRef]

159. Li, X.X.; Wang, Z.J.; Zheng, Y.; Guan, Y.F.; Yang, P.B.; Chen, X.; Peng, C.; He, J.P.; Ai, Y.L.; Wu, S.F.; et al. Nuclear Receptor Nur77 Facilitates Melanoma Cell Survival under Metabolic Stress by Protecting Fatty Acid Oxidation. *Mol. Cell* 2018, 69, 480–492. [CrossRef]

160. Maxwell, M.A.; Cleasby, M.E.; Harding, A.; Stark, A.; Cooney, G.J.; Muscat, G.E. Nur77 regulates lipolysis in skeletal muscle cells. Evidence for cross-talk between the beta-adrenergic and an orphan nuclear hormone receptor pathway. *J. Biol. Chem.* 2005, 280, 12573–12584. [CrossRef]

161. Holla, V.R.; Wu, H.; Shi, Q.; Menter, D.G.; DuBois, R.N. Nuclear orphan receptor NR4A2 modulates fatty acid oxidation pathways in colorectal cancer. *J. Biol. Chem.* 2011, 286, 30003–30009. [CrossRef] [PubMed]

162. Perez-Sieira, S.; Martinez, G.; Porteiro, B.; Lopez, M.; Vidal, A.; Nogueiras, R.; Dieguez, C. Female Nur77-deficient mice show increased susceptibility to diet-induced obesity. *PLoS ONE* 2013, 8, e53836. [CrossRef]
163. Praslicka, B.; Harmson, J.S.; Kim, J.; Rangaraj, V.R.; Ooi, A.; Gissendanner, C.R. Binding Site Analysis of the Caenorhabditis Elegans Nr4a Nuclear Receptor Nhr-6 during Development. *Nucl. Recept. Res.* 2017, 4. [CrossRef] [PubMed]

164. Jung, Y.S.; Lee, H.S.; Cho, H.R.; Kim, K.J.; Kim, J.H.; Safe, S.; Lee, S.O. Dual targeting of Nur77 and AMPKalpha by isosalantolactone inhibits adipogenesis in vitro and decreases body fat mass in vivo. *Int. J. Obes.* 2019, 43, 952–962. [CrossRef] [PubMed]

165. Stephenson, E.J.; Stepto, N.K.; Koch, L.G.; Britton, S.L.; Hawley, J.A. Divergent skeletal muscle respiratory capacities in rats artificially selected for high and low running ability: A role for Nor1? *J. Appl. Physiol.* 2012, 113, 1403–1412. [CrossRef]

166. Pearen, M.A.; Goode, J.M.; Fitzsimmons, R.L.; Eriksson, N.A.; Thomas, G.P.; Cowin, G.J.; Wang, S.C.; Tuong, Z.K.; Muscat, G.E. Transgenic muscle-specific Nor-1 expression regulates multiple pathways that affect adiposity, metabolism and endurance. *Mol. Endocrinol.* 2013, 27, 1897–1917. [CrossRef]

167. Zhang, Y.; Federation, A.J.; Kim, S.; O’Keefe, J.P.; Lun, M.; Xiang, D.; Brown, J.D.; Steinhauser, M.L. Targeting nuclear receptor NR4A1-dependent adipocyte progenitor quiescence promotes metabolic adaptation to obesity. *J. Clin. Invest.* 2018, 128, 4898–4911. [CrossRef] [PubMed]

168. Mohankumar, K.; Lee, J.; Wu, C.S.; Sun, Y.; Safe, S. Bis-Indole-Derived NR4A1 Ligands and Metformin Exhibit NR4A1-Dependent Glucose Metabolism and Uptake in C2C12 Cells. *Mol. Endocrinol.* 2013, 27, 1897–1917. [CrossRef] [PubMed]

169. Qin, D.D.; Yang, Y.F.; Pu, Z.Q.; Liu, D.; Yu, C.; Gao, P.; Chen, J.C.; Zong, C.; Zhang, Y.C.; Li, X.; et al. NR4A1 retards adipocyte differentiation or maturation via enhancing GATA2 and p53 expression. *J. Cell Mol. Med.* 2018, 22, 4709–4720.

170. Lehmann, L.H.; Jëbensa, Z.H.; Kreusser, M.M.; Horsch, A.; He, T.; Kronlage, M.; Dewenter, M.; Sramek, V.; Oehl, U.; Krebs-Haupenthal, J.; et al. A proteolytic fragment of histone deacetylase 4 protects the heart from failure by regulating the hexosamine biosynthetic pathway. *Nat. Med.* 2018, 24, 62–72. [CrossRef]

171. Pearen, M.A.; Eriksson, N.A.; Fitzsimmons, R.L.; Goode, J.M.; Martel, N.; Andrikopoulos, S.; Muscat, G.E. The nuclear receptor, Nor-1, markedly increases type II oxidative muscle fibers and resistance to fatigue. *Mol. Endocrinol.* 2012, 26, 372–384. [CrossRef] [PubMed]

172. Zhan, Y.; Du, X.; Chen, H.; Liu, J.; Zhao, B.; Huang, D.; Li, G.; Xu, Q.; Zhang, M.; Weimer, B.C.; et al. Cytosporone B is an agonist for nuclear orphan receptor Nur77. *Nat. Chem. Biol.* 2008, 4, 548–556. [CrossRef] [PubMed]

173. Li, X.; Xu, M.; Wang, F.; Ji, Y.; Davidso, N.W.; Li, Z.; Tso, P. Interaction of ApoA-IV with NR4A1 and NR1D1 Represses G6Pase and PEPCK Transcription: Nuclear Receptor-Mediated Downregulation of Hepatic Gluconeogenesis in Mice and a Human Hepatocyte Cell Line. *PLoS ONE* 2015, 10, e0142098. [CrossRef] [PubMed]

174. Fu, Y.; Luo, L.; Luo, N.; Zhu, X.; Garvey, W.T. NR4A orphan nuclear receptors modulate insulin action and the glucose transport system: Potential role in insulin resistance. *J. Biol. Chem.* 2007, 282, 31525–31533. [CrossRef]

175. Zhou, H.; Du, W.; Li, Y.; Shi, C.; Hu, N.; Ma, S.; Wang, W.; Ren, J. Effects of melatonin on fatty liver disease: The role of NR4A1/DNA-PKcs/p53 pathway, mitochondrial fission and mitophagy. *J. Pineal. Res.* 2018, 64.

176. Veum, V.L.; Dankel, S.N.; Gjerde, J.; Nielsen, H.J.; Solsvik, M.H.; Haugen, C.; Christensen, B.J.; Hoang, T.; Fadnes, D.J.; Busch, C.; et al. The nuclear receptors NUR77, NURR1 and NOR1 in obesity and during fat loss. *Int. J. Obes.* 2012, 36, 1195–1202. [CrossRef]

177. Maris, M.; Waekens, E.; Cerde, J.; Nielsen, H.J.; Solsvik, M.H.; Haugen, C.; Christensen, B.J.; Hoang, T.; Fadnes, D.J.; Busch, C.; et al. The nuclear receptors NUR77, NURR1 and NOR1 in obesity and during fat loss. *Int. J. Obes.* 2012, 36, 1195–1202. [CrossRef]

178. Kanzleiter, T.; Schneider, T.; Walter, I.; Bolze, F.; Eickhorst, C.; Heldmaier, G.; Klaus, S.; Klingenspor, M. Evidence for Nr4a1 as a cold-induced effector of brown fat thermogenesis. *Physiol. Genom.* 2005, 24, 37–44. [CrossRef] [PubMed]
180. Koenis, D.S.; Medzikovic, L.; van Loenen, P.B.; van Weeghel, M.; Huveneers, S.; Vos, M.; Evers-van Gogh, I.J.; Van den Bossche, J.; Speijer, D.; Kim, Y.; et al. Nuclear Receptor Nur77Limits the Macrophage Inflammatory Response through Transcriptional Reprogramming of Mitochondrial Metabolism. *Cell Rep.* **2018**, *24*, 2127–2140. [CrossRef]

181. Corrocher, F.A.; Bueno de Paiva, L.; Duarte, A.S.S.; Ferro, K.P.; Silveira, L.D.R.; de Lima, T.I.; Olalla Saad, S.T.; Lazarini, M. Reduced expression of NR4A1 activates glycolytic pathway in acute promyelocytic leukemia cells. *Leuk. Lymphoma* **2018**, *59*, 1501–1504. [CrossRef] [PubMed]

182. Roche, E.; Buteau, J.; Aniento, I.; Reig, J.A.; Soria, B.; Prentki, M. Palmitate and oleate induce the immediate-early response genes c-fos and nur-77 in the pancreatic beta-cell line INS-1. *Diabetes* **1999**, *48*, 2007–2014. [CrossRef] [PubMed]

183. Fassett, M.S.; Jiang, W.; D’Alise, A.M.; Mathis, D.; Benoist, C. Nuclear receptor Nr4a1 modulates both regulatory T-cell (Treg) differentiation and clonal deletion. *Proc. Natl. Acad. Sci. USA* **2012**, *109*, 3891–3896. [CrossRef] [PubMed]

184. Pei, L.; Waki, H.; Vaitheesvaran, B.; Wilpitz, D.C.; Kurland, I.J.; Tontonoz, P. NR4A orphan nuclear receptors are transcriptional regulators of hepatic glucose metabolism. *Nat. Med.* **2006**, *12*, 1048–1055. [CrossRef]

185. Navarro, M.A.; Badimon, L.; Rodriguez, C.; Arnal, C.; Noone, E.J.; Roche, H.M.; Osada, J.; Martinez-Gonzalez, J. Trans-10,cis-12-CLA dysregulate lipid and glucose metabolism and induce hepatic NR4A receptors. *Front Biosci.* **2010**, *2*, 87–97.

186. Pols, T.W.; Ottenhoff, R.; Vos, M.; Levels, J.H.; Quax, P.H.; Meijers, J.C.; Pannekoek, H.; Groen, A.K.; de Vries, C.J. Nur77 modulates hepatic lipid metabolism through suppression of SREBP1c activity. *Biochem. Biophys. Res. Commun.* **2008**, *366*, 910–916. [CrossRef]

187. Adhikari, P.; Orozco, D.; Randhawa, H.; Wolf, F.W. Mef2 induction of the immediate early gene Hr38/Nr4a is terminated by Sirt1 to promote ethanol tolerance. *Genes Brain Behav.* **2019**, *18*, e12486. [CrossRef] [PubMed]